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Numerous deaths, tragedies, and underreported drug side effects occur in outsourced 
clinical trials. Total quality system breakdowns occur even though quality agreement 
contracts and quality management systems are used by pharmaceutical organizations. The 
purpose of this single case study was to explore strategies clinical quality assurance 
managers use to avoid breakdowns in quality with outsourced clinical trials in Asia-
Pacific countries. The study included a purposeful sample of 15 clinical quality assurance 
managers from 1 pharmaceutical organization located in the Northeast region of the 
United States. The conceptual framework was von Bertalanffy’s general systems theory. 
Face-to-face semistructured interviews or e-mail questionnaires containing open-ended 
questions were used to gather data from clinical quality assurance managers who had a 
minimum of 5 years of experience with outsourced clinical trials. Coded data and themes 
were identified through the modified van Kaam method. The three emergent themes were 
the following: vendor quality management, building quality in outsourced clinical trials, 
and quality management systems. Results of the study may contribute to social change by 
helping pharmaceutical organizations’ leaders develop strategies and tools to improve the 
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Section 1: Foundation of the Study  
Background of the Problem 
Global pharmaceutical companies have been confronted with various challenges 
that affect their long-term viability. Challenges such as increased drug prices (Pronker, 
Geerts, Cohen, & Pieterse, 2011) and tighter regulatory drug approval policies to ensure 
data integrity and to prevent fraud must be addressed by pharmaceutical managers. 
Additional challenges are new clinical regulatory requirements making it difficult for 
pharmaceutical research and development (R&D) operations to perform clinical trials and 
approve a new drug (Pronker et al., 2011). The high cost of conducting clinical trials 
forces the pharmaceutical leaders to outsource clinical trials to developing countries. 
Pharmaceutical organizations address these challenges by creating an outsourcing clinical 
trial model for R&D sectors in Asia-Pacific developing countries. The outsourced clinical 
trial model saves money and time, and provides faster drug approval (Mendivil, 2012). 
Globalization of clinical trials increases complexity and makes it difficult to achieve 
global quality and patient safety (Paul, Mytelka, & Dunwiddie, 2011). According to Bate, 
Mooney, and Hess (2011), 1,589 out of 1,940 drugs were identified as registered in 
developing countries; 351 drugs were not registered, and there was limited information 
on their clinical trials and known side effects. Because of the complexity of clinical trials 
and faster completion timelines, drugs’ side effects are underreported, and unregistered 
drugs are causing thousands of deaths and hospitalizations. In addition, there are over 
3,000 deaths and 300,000 tragedies occurring in outsourced clinical trials conducted in 





 The high cost of conducting clinical trials is forcing pharmaceutical leaders in the 
United States to outsource clinical trials to Asia-Pacific countries (Mendivil, 2012). 
Outsourced clinical trials, which represent 60% of clinical trials worldwide, are causing a 
disproportionate number of deaths, tragedies, and underreported drug side effects (Soni & 
Singh, 2013). The general business problem is a disproportionate number of deaths, 
tragedies, and underreported drugs’ side effects continue to occur despite contracted 
quality standards and the inclusion of quality management systems. The specific business 
problem is some clinical quality assurance managers lack strategies to avoid a breakdown 
in quality with outsourced clinical trials in Asia-Pacific countries. 
Purpose Statement 
The purpose of this qualitative case study was to explore strategies clinical quality 
assurance managers use to avoid a breakdown in quality with outsourced clinical trials in 
Asia-Pacific countries. The targeted population consisted of clinical quality assurance 
managers from one pharmaceutical organization located in the Northeast region of the 
United States. The information provided by the clinical quality assurance managers may 
contribute to social change through the identification of strategies to avoid quality 
breakdowns with outsourced clinical trials.  
Nature of the Study 
The qualitative research method was used to explore the research participants’ 
experiences (Corbin & Strauss, 2014). Qualitative research was the appropriate method 
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because it is used to provide an in-depth description of the phenomenon from direct 
fieldwork observations, documents, and open-ended interviews (Patton, 2005). 
Qualitative research methods offered flexibility, which helped me gain a better 
understanding of the quality management system breakdowns that occur during the 
outsourcing of clinical trials (Denzin & Lincoln, 2011; Corbin & Strauss, 2014). A 
quantitative approach was not appropriate because the purpose of the study was not to 
test a hypothesis, make predictions, or evaluate cause and effect of outsourced clinical 
trials (Bernard, 2013). A mixed-methods approach was also inappropriate because the 
research question did not require both qualitative and quantitative data (Brannen & Moss, 
2012; Onwuegbuzie, Frels, Collins, & Leech, 2013). 
The design for the doctoral study was a case study. Yin (2014) noted that if the 
aim of research is to provide a rich description of a phenomenon, a descriptive case study 
is needed. The narrative study design is used to explore the life of an individual and to 
report the individual’s experiences. My research study’s aim was not to explore an 
individual’s experiences regarding outsourced clinical trials. Grounded theory was also 
inappropriate because the focus of the study was not on developing a theory grounded in 
the data from the field or studying a process or action involving many individuals. An 
ethnographic design is used to describe and interpret a culture-sharing group (Wolcott, 
2008). My research study did not focus on describing or interpreting the pharmaceutical 
culture. Finally, I excluded a phenomenological design because I did not intend to 




The central research question proposed for the study was the following: What 
strategies do clinical quality assurance managers use to avoid quality breakdowns with 
the outsourced clinical trials  in Asia-Pacific countries?  
Interview Questions 
To answer the overarching research question, the following open-ended 
semistructured interview questions were used: 
1. How do clinical quality assurance managers regulate the clinical quality 
management systems and adapt to changes when trials are outsourced to 
Asia Pacific?  
2. How do clinical quality assurance managers ensure that clinical trial 
vendors adapt to the changes in the environment and process negative 
feedback?  
3. What actions are taken by clinical quality assurance managers to ensure 
outsourced clinical trial vendors are following the agreed contracts?  
4. What strategies do clinical quality assurance managers employ to ensure 
compliance from an outsourced clinical trial vendor after an agreed quality 
contract? 
5. What are some risks and benefits associated with clinical trials when 
outsourced to Asia Pacific? 
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6. How do clinical quality assurance managers build successful relationships 
with clinical trial vendors and sustain those relationships with an ever-
changing outsourcing business model?  
7. How do clinical quality assurance managers ensure standard methods of 
communication of newly released standard operating processes, 
regulations, systems, and tools to outsourced clinical trial vendors?  
8. In a 1-year time frame, how often do clinical quality assurance managers 
and outsourcing vendors reassess quality agreements, contracts, processes, 
and potential gaps? 
9. What strategies have/have not worked with outsourcing clinical trials to 
ensure the highest quality of the clinical trial?  
10. Is there any additional information you would like add that I may not have 
addressed by the interview questions? 
Conceptual Framework 
The conceptual framework for the qualitative case study was based on general 
systems theory (Stacey, 2011). The general systems theory is a methodology used to 
employ a system approach to understanding complex problems and phenomena. The 
focus of the general systems theory is on the system structure instead of the system 
function. The core concepts of the general systems theory are (a) the whole system is 
more than the sum of the parts; (b) the system can be open, closed, or semipermeable to 
the environment; (c) feedback is the mediator between system behavior and goal; (d) the 
central variable is time; (e) change is seen as a transformation of the system; and (f) 
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defining the system environment boundaries will identify and establish what is inside the 
system and what is outside in the environment and its subparts from the system as a 
whole (Laszlo & Krippner, 1998).  
The clinical quality assurance pharmaceutical leaders are seeking an 
understanding of how to deal with information and use it for sustainable innovation 
(Senge, Smith, & Kruschwitz, 2011). The quality of clinical trials determines the 
sustainability and longevity of a pharmaceutical organization. Outsourcing clinical trials 
to developing countries such as Asia-Pacific countries adds complexity and increases 
quality risks. To address these quality risks, clinical quality assurance managers need to 
employ strategies to avoid quality breakdowns with outsourced clinical trials. The general 
systems theory served as a conceptual framework for understanding the relationships in 
the outsourced clinical trial system (Stacey, 2011). The general systems theory is used to 
understand who the individuals are, what is changing, and what the individuals are faced 
with (Stacey, 2011). Essentially the purpose of system thinking is to identify 
interrelationships rather than things. Advantages of the system thinking approach include 
helping one manage and grasp complex situations and uncertainty where there is no 
simple situation (Cezarino, Junior, & Correa, 2012).  
Operational Definitions 
Effectiveness: The extent to which improvement efforts resulted in actual 
quantifiable improvements (Golušin, Ivanović, Domazet, & Dodić, 2011).  
Offshoring: Another form of outsourcing, specifically outsourcing that happens 
aboard (Nieto & Rodríguez, 2011).  
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Outsourcing: The process of contracting out noncore activities or transferring 
activities to a third party (Crisan, Butilca, Salanta, & Ilies, 2011).  
Pharmacovigilance: A scientific activity related to the prevention, assessment, 
understanding, and detection of any drug-related issue or problem (Arici, Gelal, Demiral, 
& Tuncok, 2015).  
Standard operating procedure: The crucial part of a quality system. The global 
corporate standard operating procedures provides a standard framework of quality 
standards for clinical development. Standard operating procedures are needed to take into 
account national regulations and to describe the process at the pharmaceutical 
organization to implement at the operational level (Chaikin et al., 2000).  
System: A set of two or more interrelated elements with the following properties:  
Each element has an effect on the functioning of the whole and is affected by one of the 
other elements within the system. In addition, all possible subgroups of the elements have 
both properties mentioned above (Ackoff, 1981, pp. 15-16.)  
Total quality management: A management method used to enhance the quality of 
a business organization (Mazumder, Bhattacharya, & Yadav, 2011).  
Vendor risk: An uncertainty of choosing an appropriate vendor which ultimately 
affects the performance of a project (Mathew & Das Aundhe, 2011).  
Assumptions, Limitations, and Delimitations 
Assumptions 
Assumptions of a study are unverified claims that the researcher assumed to be 
true (Bernard, 2013). One assumption I made for this qualitative research study was that a 
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top-ranked pharmaceutical organization’s clinical quality assurance managers could 
provide an in-depth description of the quality management system’s utility in monitoring 
breakdowns of outsourced clinical trials. The second assumption was the data from 
pharmaceutical organization’s audit and inspections reports, outsourced clinical contracts, 
federal agencies reports, and clinical trial processes could be used to determine the gaps 
within the total quality management system. The third assumption was the 15 clinical 
quality assurance managers provided unbiased and truthful answers during their 
interviews. A final assumption was the outsourcing companies such as Business Process 
Organization (BPO) and Contract Research Organization (CRO) located in Asia Pacific 
were outsourcing clinical trials and had potential breaks within their quality management 
systems. 
Limitations 
Limitations in a research study are weaknesses within the study (Bernard, 2013). 
The potential weakness of the research study was exploring only one multinational 
pharmaceutical organization and not exploring medium and small pharmaceutical 
organizations. The second limitation of this qualitative study was the location of the 
outsourcing clinical trials organizations. The specific outsourced clinical trials region 
targeted for this qualitative study was Asia-Pacific countries. The outsourced clinical trial 
regions did not include Europe, South America, Central America, North America, and 
Africa. The third limitation was the study participants were from one pharmaceutical 
organization located in the Northeast United States. The fourth limitation was the 
exclusion of outsourced contract research organization’s participants. The final limitation 
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was the inclusion of clinical quality assurance participants and exclusion of all other 
quality assurance and clinical trial participants. 
Delimitations 
The researcher’s selection of the scope or boundaries of the study define the 
delimitations (Bernard, 2013). The scope of the study was to explore the quality 
management system from one pharmaceutical organization, which was responsible for 
performing a particular research development function of the clinical trials. The study did 
not include any clinical quality assurance participants outside the Northeast United 
States. Clinical quality assurance managers with less than 5 years of experience were not 
in the study. The purpose of this qualitative study was to explore the strategies clinical 
quality assurance managers needed to avoid a breakdown in quality with outsourced 
clinical trials in Asia-Pacific countries. Therefore, the scope of the study included only 
clinical quality assurance managers, and all other clinical line functions were excluded. 
To understand why breakdowns occurred in outsourced clinical trials, only clinical trial 
processes, clinical regulations, and clinical quality management systems were in scope. 
All other nonclinical processes and systems were out of scope. 
Significance of the Study 
Contribution to Business Practice  
The research study showed the benefits, risks, and quality issues associated with 
outsourcing clinical trials to Asia-Pacific countries. The data collected from this research 
study may help pharmaceutical organizational leaders contribute to the effective practice 
of business by assessing their outsourcing business model and quality management 
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systems. In addition, the data can also enhance quality agreements between 
pharmaceutical organizations and outsourcing clinical trial companies to reduce audit 
inspection findings and increase approval time on new drugs. 
Implications for Social Change  
The information provided by clinical quality assurance managers contributed to 
social change through the creation of strategies to improve quality with outsourced 
clinical trials. The results may also be used to develop outsourced clinical trial best 
practices and standard operating procedures. The quality improvements with outsourced 
clinical trials may produce more effective, safer medicinal products. The quality 
improvements made within the clinical trial processes may provide knowledge of the 
quality of the drug and the adverse events associated with the medicinal product, which 
may ultimately help the public understand the risks related to the medicinal product.  
A Review of the Professional and Academic Literature 
The purpose of this section is to provide a review of the literature to describe 
various pharmaceutical challenges that are forcing pharmaceutical leaders to outsource 
clinical trials to Asia Pacific, and to explain why quality breaks occur after signed quality 
contracts. To understand this phenomenon, I conducted a literature review for clarity and 
insight (Marshall, 2010). I provided critical analysis and synthesis of various sources of 
literature such a government agencies’ reports, clinical regulations requirements, peer-
reviewed journals, books, and dissertations. Scholars addressed the pharmaceutical 
outsourced clinical trial model and the various quality risks and concerns in the following 
areas: (a) pharmaceutical challenges, (b) outsourcing, (c) top destination for outsourcing 
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clinical trials, (d) outsourcing clinical business process, (e) outsourcing key risk factors, 
(f) total quality management with pharmaceutical organizations, (g) quality of clinical 
trials, and (h) clinical trials process improvements. For the professional and academic 
literature in the doctoral study, the focus is to review peer-reviewed books, journal 
articles, doctoral dissertations, and government websites. I used the Walden University 
library databases to search for peer-reviewed journal articles, books, and dissertations. 
Databases included ABI/INFORM Global, ProQuest, and SAGE Publications. I also used 
Google Scholar to search for relevant literature. I employed the following search terms to 
locate information: outsourcing in Asia, outsourcing clinical trials, outsourcing risks, 
pharmaceutical challenges, quality systems, offshoring, general system theory, clinical 
trial regulations, total quality management, and continuous process improvement. This 
strategy assisted in identifying leading scholars and their studies. Integration of this 
knowledge supported this study (Marshall, 2010). The literature review consisted of 95 
peer-reviewed journal articles, government reports, dissertations, and books; 82 (86%) 
were published within 5 years of the study.  
The purpose of this qualitative case study was to explore strategies clinical quality 
assurance managers use to avoid a breakdown in quality with outsourced clinical trials in 
Asia-Pacific countries. The literature review supported the research study’s conceptual 
framework and provided information regarding its application (Brown-Jeffy & Cooper, 
2011). I used Ludwig von Bertalanffy’s (1968) general systems theory to understand the 
complex problems of quality breakdowns with outsourced clinical trials.  
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General Systems Theory 
The conceptual framework for the qualitative case study basis was the general 
systems theory. The general systems theory is a methodology employed to understanding 
complex problems and phenomena. The concept of system science emerged due to the 
response of individuals wanting to understand and deal with complexity. The system 
theory started to emerge in the 1960s as a uniformed approach to understanding 
environmental factors as well as humans and how they interplay with human 
development and functioning (Germain, 1994). According to Laszlo and Kippner (1998), 
the concept of the system theory is that the system is characterized by the interaction of 
its components and knowing one part of the system allows information to another part of 
the system.  The approach drew upon the application of the human activity system as well 
as the general system theory. Hall and Fagen (1956) defined the term environment in the 
system theory any change to the subject or environment can attribute to systems changes 
and the behavior. Germain (1994) described two system theories: the social system 
theory and the general system theory. According to Germain, both system theories had a 
common interest in the living system and could be used to view an individual as a 
system. The difference between both system theories was the general systems theory was 
from physical science, biologics, and cybernetics, and the social system theory derived 
from social psychology, sociology, and symbolic interactionism (Germain, 1994). Ackoff 
(1981) argued that the social system environment contained three purpose levels: the 
parts of the system, use of the system, and the supra system. 
13 
 
The general systems theory was founded in 1928 by von Bertalanffy; however, it 
was not until 1968 that a true scientific breakthrough occurred with the publication of the 
general system theory (Norlin & Chess, 1997). Von Bertalanffy grew quite dissatisfied 
with the cause-and-effect theories to explain the change observed in living organisms and 
decided to discover a definitive cause of a system relationship. Von Bertalanffy (1968) 
searched to understand the order among the parts in the system, and not to focus on them. 
Until this discovery by von Bertalanffy, a scientist focused on the reductionist process 
based on linear causation to understand the whole system by examining the individual 
parts, not how the parts related to each other (Norlin & Chess, 1997).  
Von Bertalanffy argued that societies, organisms, and human organisms are open 
systems. Also, von Bertalanffy explained that there are systems that have a number of 
subsystem components that are interrelated and interdependent (Stacey, 2011). In an 
organization, subsystem components related to the control and management information 
systems and the cultures that kept harmonious teams working together. The general 
systems theory recognizes that a whole system needs to maintain a form of control or the 
subsystems will become out of balance over time. Inevitably, the system will be out of 
balance with the environment as well as each other (Stacey, 2011; von Bertalanffy, 
1968). However, adaptive mechanisms exist within an organization that promotes 
changes and keeps it in equilibrium with the environment. Ultimately, there is an 
inevitable conflict between the two subsystems; however, according to the general 
systems theory, a successful organization will sustain equilibrium (Stacey, 2011).  
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According to Stacey (2011), the general systems theory includes the following 
organizational dynamics: 
 It is up to leadership to manage boundaries and to regulate the system, so 
it adapts to changes. 
  Successful management will ensure the system adapts to the changes in 
its environment and process negative feedback producing stable 
equilibrium. 
  An organization is an open system, a set of interconnected parts that 
interact with other individuals and organizations outside of it. 
  A system imports information and energy from outside itself, and 
transforms both the energy and information in some way to export the 
transformed results to a system outside itself. 
  Organizations should import systems by: (1) import across a boundary 
separating it from other systems, (2) transform the imports within its 
boundary, and (3) export back across the boundary separating the system 
from the environments. 
  Success is state of harmony, stability, and consistency. 
  The relationship across the boundary is ever changing, the environment 
will always change, and the boundary needs a regulatory function. 
  Adaption to the environment determines the stable equilibrium between 
integration and differentiation, between the control system and 
maintenance change required for success.  
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As globalization developed, Godfrey (2010) asserted that interdependence becomes more 
relevant and the complexity of the problems the organization needs to resolve increases. 
Consequently, the organizational need for a sustainable environment is urgent (Godfrey, 
2010). Organizations use a system thinking approach for these complexities. 
Pharmaceutical managers use system thinking as a way to resolve complex problems and 
designs. Essentially the framework for system thinking is to seek interrelationship rather 
than things. Advantages for the organization using the system thinking approach include 
leaders managing and grasping complex situations and uncertainty where there is no 
simple situation. Godfrey (2010) summarized this approach as the practical holism when 
the organization learns of an effective action by looking at connections rather than parts 
separately (Godfrey, 2010). The three key framework ideas for the system are processes; 
layers, parts, and wholes; and connections (Godfrey, 2010). 
Quality Management Systems  
In a clinical setting, it is difficult to measure quality. Quality systems require 
implementation and development of standards within each step. Even though this 
requirement is not new to clinical research, a systematic approach will produce more 
reliable, high-quality data and a more useful product without compromising patients’ 
rights (Human Information Technology, 2014). There are several general requirements 
that can improve quality systems such as training, personal roles and responsibility, 
policies and procedures, quality assurance and auditing, document management, record 
retention, reporting, and corrective and preventative action (Kleppinger & Ball, 2010). 
Personal roles and responsibilities need to be communicated and documented for the 
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clinical trial research team. It is essential for a clinical research team to create a 
delegation log to create accountability for each member in the clinical trial. The 
responsibility of training falls under the sponsor. It is up to the sponsor to ensure the 
research investigator and clinical research staff are appropriately trained and qualified to 
conduct a clinical trial (Collaborative Institutional Training Initiative (CITI), 2014). The 
clinical research team needs mandatory training in good clinical practices and human 
subject protection. It is essential that sponsors have policies and procedures in place to 
approve a robust Good Clinical Practice (GCP) training to the research staff as well as 
periodic refresher training. Food and Drug Administration (FDA) Regulations (2015) is 
also in agreement with the training requirement within the quality system by stating in the 
regulations when there is an investigational product within the clinical trial all key 
clinical research personnel should be knowledgeable of all applicable regulations, 
including those that pertain to human subject protections. Furthermore, it is also a 
training requirement for the clinical research team to train on the clinical protocol and 
document the training of the protocol. Finally, to ensure the adequacy of the training, a 
knowledge test is highly recommended (FDA Regulations, 2015).  
Before the investigator or sponsor writes any protocol, it is essential for the 
investigator or sponsor to be well aware of his or her institution’s procedures and 
policies. This can include, but may not be limited to, the handling of biological samples, 
protocol review procedures, confidentiality agreements, human subject protections, data 
management, and procedures for handling possible scientific misconduct (Code of 
Federal Regulations (CFR) 21a, 2015). An essential policy for the institution to have is 
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the record retention policy, which would specify a longer retention time frame than the 
one required by the federal agency (CFR 21b, 2015). It is critical for institutions to have 
written standard operating procedures (SOPs) in place for each clinical site. 
Standardization with clinical research SOP templates is essential to provide quality 
documentation standards within all clinical line functions (Clinical Trial Network 
Business Practice (CTNBP), 2014). It is imperative that SOPs be reviewed periodically to 
adhere to new regulatory requirements and updated processes and for all staff to 
adequately document SOP training (CTNBP, 2014). Another critical component in the 
quality system is to include quality assurance and auditing. Clinical trial teams are 
familiar with a sponsor audit or a regulatory agency audit. Clinical trial teams are well 
aware of the scrutiny of an audit when it comes to clinical database systems and quality 
assurance procedures (Kleppinger & Ball, 2010). If there is no implementation of quality 
assurance programs within the investigators’ sites, there is no quality oversight 
(Kleppinger & Ball, 2010).  
Other essential components of the quality system are document management, 
record retention, and reporting. All staff should understand documentation of archival 
procedures, and staff should demonstrate an understanding of these systems. Handling of 
documentation such as tracking, filing, conventional naming, document version control, 
and systematic backup of real-time data collection should follow standardized 
procedures. All clinical documentation should be in a locked area with restricted access. 




 The final component of a quality system is corrective and preventive action. 
Clinical trial teams should document clinical trial quality breaks and corrective 
preventative actions within the quality system to avoid any potential agency findings. 
Potential problems will always arise in an outsourced clinical trial; however the discovery 
of the potential issue should have an effective corrective and preventative action 
assigned. After an allotted amount of time passes, clinical trial teams should perform an 
effectiveness check to ensure the problem would not recur. According to Grignolo 
(2011), the Clinical Trial Transformation Initiative, there are four key components 
consisting of management responsibility, resource management, process management, 
and improvement. Garza-Reyes, Rocha-Lona, and Kumar (2014) presented similar views 
to Kleppinger and Ball (2010) that many organizations should turn to a quality 
management system to provide high-quality products and customer satisfaction. Rocha-
Lona, Garza-Reyes, and Kumar (2013) argued that to obtain high-quality standards, 
organizations need to integrate the quality management system and deploy quality 
management tools and methods across the whole organization. Garza-Reyes et al. (2014) 
had slightly different elements of their quality management system (QMS) and 
categorized them by processes, human capital, business strategy, information technology, 
and management models-methods-tools. To have an effective quality management 
model, tools, and methods; organizations refer to the ISO guidelines, six sigma, lean and 
business techniques, total quality management (TQM), process re-engineering and 
business excellence models (BEMs) (Asif, Searcy, Garvare, & Ahmad, 2011; Garza-
Reyes et al, 2014). When organizations develop a well-structured integrated QMS, it 
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provides a competitive advantage for customer satisfaction and higher quality products 
(Asif et al., 2011; Garza-Reyes et al., 2014; Jones, Parast, & Adams, 2010; Kanji, 1996).  
Some of the gaps that existed in the quality management literature were that the 
authors did not discuss the effectiveness or non-effectiveness of the quality management 
system through quality metrics. If the authors discussed, quality metrics within the 
literature for quality management system, they would provide the audience knowledge on 
organization performance. In addition, there was no discussion on what the common 
reasons were that breaks occurred in QMS, even though the organizations had the 
appropriate total quality management model. 
Quality Management System Within a Pharmaceutical Organization  
Quality is an essential component of the pharmaceutical industry. Johnson and 
Gupta (2013) defined quality as providing practical solutions to the queries about the 
profits and dangers of a drug process while guaranteeing safety for human subjects. To 
fulfill the regulatory requirements, the sponsors need to enhance quality by improving 
systems and processes (Cerullo et al., 2014; Hanfield & Gosh, 2004; Johnson & Gupta, 
2013) with definite standards for every clinical test procedure. It is mandatory for the 
sponsors of clinical trials, business process organizations, and contract research 
organizations to establish, maintain, control, and monitor both the quality assurance and 
quality control systems. In addition, for organizations that follow the systems’ standard 
operating procedures and other clinical quality documents provide the highest quality 
product and services to meet customers’ needs and expectations (Johnson & Gupta, 
2013). For a clinical study to have quality, it must include an experimental design that is 
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scientifically and ethically sound; protection of the subjects’ rights, safety, and welfare; 
competent personnel; adequate surveillance; and current, complete, and exact data. In 
recent years, regulatory agencies have become stricter on clinical trials specifically 
regarding patient security and data credibility (Johnson & Gupta, 2013). According to 
Johnson and Gupta (2013), the main purpose of the regulatory agencies is to execute the 
principles of quality management in health research to impede downfall, maximize the 
use of valid resources, and guarantee consistency and dependability of outcomes. 
Quality management system success factors Pharmaceutical organizations 
utilized quality management systems to improve the quality of product and process to 
achieve continuous customer satisfaction (Khanna, Sharma, & Laroiya, 2011). 
Implementation of quality remains an important issue for global organizations, which are 
continuously trying to improve their competitiveness (Khanna et al., 2011; Johnson & 
Gupta, 2013). The R&D organizations are facing an evolving environment, which is 
rapidly changing due to globalization. Indian R&D organizations specifically are in dire 
need for new approaches, strategies, and techniques to have a competitive advantage 
(Khanna et al., 2011). One question asked by many organizations (Khanna et al., 2011; 
Johnson & Gupta, 2013) is why with the implementation and benefits of quality 
management systems do many Indian R&D organizations face numerous implementation 
problems? Quality management remains a challenge because the decision makers within 
the organization are not prioritizing critical success factors. For an organization to adopt 
new quality management systems, produces high risk due to the high cost associated with 
adoption. One of the standard practices in India is to select training and then adapt to 
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process carefully using various methods to reach the final decision. In order to achieve a 
competitive edge, organizations have shifted priorities from a low-cost production to 
quality, dependable delivery, flexibility, and short lead-time. They also implemented new 
philosophies and information technology such as quality management systems, Six 
Sigma, lean, business process re-engineering and business excellence models, which 
claims to support an organization's improvement efforts (Thawesaengskulthai and 
Tannock, 2011; Khanna et al., 2011). Indian organizations realized that they would not 
gain competitive advantage without being quality conscious (Khanna et al., 2011). The 
quality management system implementation depended on several factors such as 
communication, management commitment, and employee involvement (Kanji, 1996).  
Quality management system critical success factor For QMS implementation 
to be effective within the organization, it involved the defining and deploying critical 
success factors (CSF). These factors included the hard factors such as systems, tools, and 
techniques, as well as, soft factors such as employee commitment and leadership (Khanna 
et al., 2011). The CSFs are the factors that can significantly affect the organization and 
required particular attention in the quality management systems. The CSF provided signal 
detections of early warning risks within management systems and avoids any surprises. 
In order for the successful QMS implementation, the organizations should  have a 
thorough understanding CSFs and adoption of the QMS implementation (Salahedin, 
2011; Khanna et al., 2011). One of the key points in the literature reviews (Khanna et al., 
2011, Salahedin, 2011) is the ranking of the CSFs in the quality management 
implementation to reduce costs, increase success rate, and prevent failure.  
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Top management leadership is a vital factor because it is important for 
management to provide enough resources to ensure quality achievement, as well as, 
understand the concept of quality and importance of it. Management needed to 
understand and identify quality management goals and demonstrate understanding those 
objectives. One of the gaps in management leaders is their lack of intention of the quality 
management system. As well as, how it is implemented in various line functions within 
the organizations (Khanna et al., 2011). The second CSF is supplier quality management. 
Supplier's management focused in on the effectiveness of the quality management system 
within the organization. The relationship between supplier and organization is an 
important relationship to maintain (Khanna et al., 2011; Salaheidin, 2011). In order to 
have an active relationship, the organization had few supplier rather than many suppliers. 
There should be a clear understanding of each other expectations and each other's 
processes to ensure quality products. The organizations’ expected proper quality 
management systems in place to measure/monitor delivery performed and quality of the 
product and has knowledge information exchanges with the supplier on the regular basis 
(Khanna et al., 2011). The third factor is process management. Process management 
should meet the criteria of the international organization for standardization (ISO) 9000 
standards (Khanna et al., 2011; Candido & Santos, 2011). Frequent reviews of all aspects 
of clinical and manufacturing operations should be down and any corrective and 
preventative actions implemented. The identification of key processes and improved 
continuously to achieve higher quality with the product (Khanna et al., 2011). The fourth 
CSF is human resource management. Human resource management focus is to empower 
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employee management within the organization. Human resource management 
encouraged employees to innovate and contribute quality continuous improvement 
processes (Khanna et al., 2011). Quality management within pharmaceutical organization 
focused on an open quality culture, teamwork, and having sustainable continuous 
improvement. Quality management required human resources management systems to be 
in place to support this focus. The systems allowed information exchange between human 
resource and employee to ensure that employees are aware of the role and 
responsibilities, goals and objectives, and job training. The fifth CSF is customer 
satisfaction. Customer satisfaction in quality management focuses on the quality measure. 
The more satisfied the customer, the greater the quality measure. Organization should 
have systems in place to receive complainants and feedback. The sixth factor is the role 
of the quality department within the organization. The quality assurance department 
should have clear objectives, vision, missions, systems, quality policies and tools in place 
to implement a viable total quality culture (Khanna et al., 2011). The seventh factor is 
training. Training places a crucial role in the implementation of the quality management 
system. Khanna et al. noted quality management system key focus is adequate training 
and education of employees to improve their knowledge and skills. It includes general 
training as well as specific training and retraining of the employees. It provides a base for 
communication of new organizational strategies to the employees. The eighth factor is 
quality citizenship. Quality citizenship is when the organization adopts an ethical 
standard that allows the accountability and transparency of key stakeholders for their 
organizational performance. They promote both social and corporate responsibility and 
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environmental sustainability both in the present and the future. The ninth CSF is a quality 
system and information technology. To collect information on data such as cost of quality 
data, scrap data, and rework data; an effective and efficient system should be in place. 
The information system should enable data be transparent, collected in a timely manner, 
and provides feedback to the employees. The outputs of these systems allowed to 
measures quality performances (Kanji, 1996). The use of IT has a profound effect on 
quality managements by contributing to the enhancement of quality awareness, reduction 
of quality costs, improvement of product and processes. Finally, there is the product 
design. Product design is an important factor in the quality of the product. Product design 
must meet with quality standards, ethical standards and meet with regulatory 
requirements (Johnson & Gupta, 2013). Product design ultimately effects if the product to 
the customer is right or wrong and if it will meet the customer satisfaction. Johnson and 
Gupta, Khanna et al., and Saleheldin  discussed quality management systems, 
implementation, and the success factor, which will assist organizations to succeed in 
implementation. However, one gap that exists, there is no detailed discussion of 
unsuccessful factors that causes the quality breakdown with quality management systems. 
By addressing both successful, and unsuccessful factors provides the reader a 
comparative to understand why the factors were categorized success and unsuccessful.  
Quality management system implementation barriers One common failure 
factors of quality management system within an organization is improper implementation 
(Cândido & Santos, 2011; Dahlgaard-Park, 2011; Hoonakker, Carayon, & Loushine, 
2011; & Kanji, 1996). Many organizations’ find it difficult to effectively implement 
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quality management systems, which in turn have lost the momentum to adopt an efficient 
model and instead have only set quality management system initiatives (Cândido & 
Santos, 2011; Manjunath, & Kumar, 2013). Due to the difficulty of implementing quality 
management system, there is a decline rate within many organizations in adopting quality 
management systems (Cândido & Santos, 2011; Dahlgaard-Park, 2011) and instead are 
turning to other management strategies such as ISO 9000 management strategies 
(Cândido & Santos, 2011). There is a common theme among the literature review by 
authors Cândido and Santos, Dahlgaard-Park, Hoonakker et al., Kanji, Manjunath and 
Kumar, and Moballeghi (2014) agreed the reason for failure of many organizations 
quality management system models is that it requires total quality cultural change for 
everyone within the organization. In addition, there is also agreement that top managers 
and executive leaders need to take an active leadership role have the commitment from 
everyone within the organization committed to the quality goals. 
Sebastianelli and Tamimi (2011) acknowledged additional factor analysis of QMS 
barriers, which reveals five common obstacles such as lack of customer focus, inadequate 
resources of QMS, inadequate human resources development and management, lack of 
quality planning, lack of leadership for quality. As well as, provided framework for 
evaluating the significance of top management related obstacles for QMS success, as well 
as, provided additional guidance in developing strategies for a complete and effective 
QMS transformation (Sebastianelli & Tamimi, 2011). Yusof and Aspinwall (2011) 
introduced other QMS barriers, which are not mentioned by other authors such as training 
and development of staff at ad hoc can hinder improvement effort. In addition, the lack of 
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financial resources, this can affect organizational processes as well as management not 
delegating a task, which can stifle teamwork. All of the elements above can hinder QMS 
implementation, and there is a vast literature on how QMS can help to improve the 
quality and how difficult it is to implement. However, there is scarce current works of 
literature that provided a framework for organizational leaders to develop strategies to 
have an effective QMS in their outsourcing the models in developing countries 
(Moballeghi, 2014). A gap in the literature it does not discuss the difficulties that 
developing countries have in identifying QMS barriers and critical success factors of 
QMS implementation (Moballeghi, 2014). As the trend to outsource to developing 
countries is becoming part of many global organizations, the focus for future studies on 
how to implement a successful QMS implementation. Furthermore, the study’s aim of 
proper guidance to benefit manager within these developing countries where there is a 
lack of information on how to overcome these implementation barriers and can promote 
new systematic way of thinking in various cultural context (Moballeghi, 2014). One of 
the gaps in literature is there is no analysis of what an organization does after identifying 
QMS barriers. There is no clear guidance for an organization to remove a QMS barrier. 
The final gap in the literature is QMS success factors are implemented within the 
organization; however, sustainability is not discussed (Asif, Searcy, Garvare, & Ahmad, 
2011). I think if future studies address these gaps in the literature more global 




Pharmaceutical Organizations Challenges 
Pharmaceutical organizations are faced with various challenges that relate to 
regulations, advance in technology, globalization, product competition, innovation of 
new knowledge, and outsourcing (Duppada & Aryasri, 2011). Outsourcing clinical trials 
is the biggest trend of pharmaceutical business approach to gain the competitive 
advantage, to gain quicker regulatory approval, and to produce efficient and effective 
clinical trials by outsourcing organizations (Kara, 2011; Sharma, 2010). Pronker et al. 
(2011) agreed with Kara that due to the drug price increase the supply chain is under 
scrutiny. The drug pipeline is decreasing, and the cost of drug development is increasing. 
Consequently, this is leading to more out of pocket expenses for patients for drugs.  The 
increase of drug development costs and having a competitive advantage is leading 
clinical trials and research development functionality to outsource to India.  
There are vast amount of peer-reviewed literature, which analyzed the challenges 
that pharmaceutical organizations face. Hafner and Popp (2011) and Lamittina (2012) 
discussed some these challenges, such as tremendous amount of the financial loss to other 
generic organizations when patent expires. For example, the top ranked pharmaceutical 
companies such as Bayer lost its patent rights to Nexavar, Roche lost patent for Tarceva, 
and Pfizer denied the patent rights to Stuten and lost billions of dollars. The effect of the 
tremendous amount of financial loss causes the pharmaceutical company to consider 
outsourcing. 
Pammolli, Magazzini, and Riccaboni (2011) agreed that the pharmaceutical 
organization specifically in research and development are facing tremendous challenges. 
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One of the challenges the R&D organization face is complexity in the productivity of the 
pipeline. Pharmaceutical R&D productivity from the mid-1990 has experienced a 
downturn. From 1998 to 2008, the number of new molecular entity approved per year as 
declined. According to recent estimates, the average time to pass approval through US 
clinical trials ranges from six years to eight years (Pammolli et al., 2011). Innovation in 
pharmaceuticals is a cumulative process, and, unfortunately, the markets where effective 
compounds are available there is high POS. In the established markets, the patent 
innovates drugs are at the same level as the older drugs. Consequently, R&D investments 
tend to focus on new therapeutic targets, which are characterized by high uncertainty and 
difficulty, but lower expected post-launch competition (Pammolli et al., 2011).  
Adobor (2012) also agreed on the increasing challenges such as increasing speed 
in drug development, domestic cost increase, various challenges of competition, 
emerging markets, global clinical sponsors, outsourcing critical parts of the value chain 
activities specifically drug testing and contract clinical organization is causing ethical and 
moral issues. There are advantages for pharmaceutical giants to outsource medical 
research for lower cost to Asia Pacific. However, the contract medical research that is 
being outsourced is in jeopardy until the ethical issues and concerns associated with 
outsourcing business models are not being addressed or recognized. One gap in the 
literature is there is discussion on challenges that pharmaceutical organizations face, 
however, there is no discussion in the literature on how the challenges affect the 
pharmaceutical organization such as employee morale, loss of jobs, adapting to new 
culture and technology. 
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Drug development costs According to Rosier, Martens, and Thomas (2014), the 
estimated cost of the drug development can range from 800 million US dollars to 1 
billion. Investments for pharmaceutical companies in the development of new drugs is a 
considerable risk, due to the fact it is unknown if the new drug is safe in patients until the 
end of drug development (Rosier et al., 2014). American's spend $2.6 trillion dollars on 
healthcare last year (Hassanzadeh, Modarres, Nemati, & Amoako‐Gyampah,2014) and 
the healthcare expenditure shows over 12.9% of total expenditures is with the 
pharmaceutical and it is the fastest growing portion of healthcare spending (Hassanzedeh 
et al., 2014). There is an agreement between the authors this is at the increasingly high 
prices of prescription drugs, especially with specialty drugs and brand names, and rising 
associated costs with research and development of new drugs. Pharmaceutical 
organizations argue the rise of cost is due to the fact the process of drug development in 
R&D is extremely expensive and requires substantial capital expenditure (Hazzanzedeh 
et al., 2014; Drain, Robine, Holmes, & Bassett, 2014). For a pharmaceutical organization 
to make a cancer drug, it cost them around $1.75 billion for R&D and almost ten years to 
grow through the various test and market. American pharmaceutical organizations alone 
spend over $45 billion on developing new drugs or modifying current drugs. 
Outsourcing 
For the pharmaceutical organization to meet the challenges of increasing cost of 
drug development and stricter regulation, they are turning to outsourcing clinical trials. 
Outsourcing consists of operation functions or transferring of internal functional services 
to a third party service provider and controlling the sourcing through the partnership or 
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contract management (Mariani, Falotico, Zavanella, & Mussini, 2014). A vast amount of 
literature provided the benefits and motivations for pharmaceutical organizations to 
outsource. The three major reasons for motivation for outsourcing are target health 
policies, public health development strategies, and public spending cuts (Mariani et al., 
2014). Outsourcing does provide potential benefits, however there are also several 
disadvantages ( Mariani et al., 2014; Roberts, 2001; & Sharma, 2010 ) cost savings is 
lower than expected and not available over the long term; liability for vendor action, 
being over-dependent on vendors and losing control over the standard of service 
delivering (Mariani et al., 2014).  
The outsourcing of various functional departments within R&D, to CRO or BPO, 
is a frequent practice (Huysmans et al., 2014) among pharmaceutical organizations to 
lower costs and achieve faster approval timelines. However, the majorities of the 
outsourcing projects are prone to failure (Huysmans et al., 2014) and increase costs for 
pharmaceutical organizations to repair the damage. Due to the high risk of failure, many 
scholars suggest a variety of outsourcing risk factors that leads to unsuccessful project 
outcomes, as well as possible remedies to mitigate them. There are many empirical 
studies, which continue to report frequent failures in outsourcing projects. Huysmans, De 
Bruyn, Beazeer et al. (2014) used the concept of modularity for an alternative perspective 
to analyze risks related to outsourcing projects. The approach assisted in supplementing 
existing outsourcing risk analyzes with new, additional, or more profound insights into 
outsourcing risks. In addition, it served as an additional basis to list a more exhaustive 
enumeration of required mitigating actions, which leads to successful outsourcing 
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projects (Huysmans et al., 2014). In the BSkyB, the case showed the alternative 
perspective that illustrates a reanalysis of a failed outsourcing case documented in the 
literature and available court proceedings. According to Huysmans et al. the BSkyB case 
shows the specific way how the poorly designed modular structures at the project 
communication, technical, and project management level could identify ex-ante. The 
identification explained the manifestation of ex-post outsourcing risk factors such as 
managing user expectation, lack of required skills, managing user expectation, 
communication problems, project management, and significant integration requirements. 
Top destinations for outsourcing clinical trials The author Langer (2011) 
provided an in-depth analysis of benefits and risk to outsourcing to India and China from 
the intellectual property. The comparison of the large pharmaceutical companies of the 
research and development spend provided excellent data on how much each company is 
spending on R&D costs. The author slightly touched on the quality aspects, however not 
much detail or analysis on the breakdown of the quality and the recovery from it. Surve 
and Tembhurne (2013) drew the same conclusion as Langer that India and China are the 
top destinations for outsourcing. Surve and Tembhurne discussed how the trend for 
pharma and life sciences industry is favoring of outsourcing both research and 
manufacturing to India. India became the most sought out destination for outsourcing due 
to low cost (Drain et al., 2014). Frost and Sullivan (2011) study results showed India's 
contract research and manufacturing estimated at $895.44 million in 2006 and increased 
43 percent over the previous year. Clinical research currently is 16% of their revenue. 
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The leading driver to outsource clinical trials to India costs and compliance issues are 
becoming prohibitive for them in the West.  
Novak, Beloserkovsky, and Payeur (2014) acknowledged there are changes in the 
geographical regions in the global clinical trial landscape. The reasons for increase global 
clinical trials:  (a) increased prevalence of chronic diseases, (b) aging population, (c) the 
embrace by physicians and payers of evidence-based medicine, (d) and patient's common 
belief that they will benefit from treatment and medical technology, and (e) access to 
medical treatment through participation in clinical trials (Novak et al., 2014). The newly 
growing regions for clinical trials have moved to East Asia, and South Asia is the fastest 
growing regions. A great hike has registered with China by +30% and South Korea by 
+29%. Both countries represent almost +7%. India has the most significant growth at 
40% due to the considerable advantages such as the acceptable quality of services and 
good patient recruitment (Novak et al., 2014).  
A recent research study conducted by Yathindranath, Kureishi, Singh, et al. 
(2014) in the evolution of clinical trial landscape of Asia Pacific explores the increase in 
global trials in the region. The method used for the study was an extraction of clinical 
trial data from 15 commercially available online databases for global clinical sites and 
trials including Asia registries. The clinical trial registries such as: Australian New 
Zealand Clinical Trials Registry, ClinicalTrials.gov; the International Standard 
Randomized Controlled Trials Number; Clinical Trials Registry, India; Clinical Research 
Information Service, Republic of South Korea; Japan Primary Registries Network; the Sri 
Lanka Clinical Trials Registry assisted with gaining access to the data (Yathindranath et 
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al., 2014). In order to analyze the latest trends in Asia Pacific, two-time periods (2009-
2010 and 2011-2012) were collected. The results from the study showed that in 
comparison of the two-time periods Asia Pacific is stable with the volume of clinical trial 
site numbers and clinical trial numbers. The primary destinations for agencies inspections 
there are the change in geography, therapeutic areas of clinical trials observed and 
conducted. The study concluded the top ten destinations in Asia Pacific for major clinical 
trials destinations are Taiwan, Japan, South Korea, India, and People's Republic of China 
(Yathindranath et al., 2014). The rising standard of medical care and the standard of 
living in developing countries such as Vietnam, Philippines, and Indonesia is causing an 
increase in local clinical trials.  
The major component of the increase in global drug development is the 
emergence of Asia. Asia is still in the infancy phase when it comes to the perceived 
potential in the pharmaceutical industry; however, growth is steadily increasing. The 
reason for growth is due to the financial consideration of the clinical trials such as 
reduced per patient costs and shorter recruitment timelines, which are primary drivers of 
the growth (Horsburgh et al., 2014). One of the active contributors to the growth of 
clinical trials in Asia Pacific is oncology. The rapid growth in Asia Pacific is due to the 
total investigator site pool, as well as, the number of experienced and inexperienced or 
naïve sites, which are being, activated (Horsburgh et al., 2014). In April 2013, more than 
9,000 ongoing clinical trials in Asian Pacific countries were listed in the 
ClinicalTrials.gov database, 20% of the global clinical trial landscape (Horsburgh et al., 
2014). Twenty-seven percent consisted of Asian-Pacific studies were Phase I, Phase II or 
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Phase III oncology trials. Additionally, less than 10% of all patients enrolled during the 
observed period were involved in oncology studies. 
Outsourcing clinical business processes. Pharmaceutical organizations 
increased sourcing their clinical business processes through third party service providers, 
a standard practice known as BPO. Globally, the BPO market earns $279 billion dollars 
in their clinical trial services, and it will continue to grow at 25% annually (Lacity, 
Solomon, Yan & Willcocks, 2011). In the last 15 years, many academic researchers 
studied this market and produced findings relevant to practice. In previous research, 
many outsourcing vendors have been reviewed; however, the entire body of BPO 
research has never been considered. Lacity et al. conducted a study to fill this gap. The 
research consists of total studies and reviews 87 empirically robust BPO articles 
published between 1996 and 2011 in 67 journals to answer three research questions: 
What has the empirical academic literature found about BPO decisions and outcomes? 
How do BPO findings compare with Information Technology Outsourcing (ITO) 
empirical research? What are the gaps in knowledge to consider in future BPO research? 
The study provides researchers of a broad overall broad understanding of BPO. However, 
the BPO practice continues to evolve as more pharmaceutical clients and suppliers on 
every continent are actively participating in the global sourcing community. One gap that 
remains is a quality of the BPOs’ clinical trial processes provides for their pharmaceutical 
client.  
Lahiri, Kedia, and Mukherjee (2011) agreed with Lacity et al. (2011) there are 
significant gaps in the understanding the context of the offshoring service providers. 
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However, even though there are gaps in the research on understanding BPO as a whole, 
many organizations still outsource their business processes. Essentially, organizations 
disaggregated their value chain and transition over their parts to the providers for a 
successful delivery and execution of the processes. The primary inspiration for an 
organization to move to BPO is cost savings, adding flexibility of business operations, 
greater risk spreading, increased focus on core business activities, and reduced to market 
(Lahiri et al., 2011). For BPO to partake in the rapidly growing market, they offer a wide 
variety of value-added services to their expertise. BPO are no longer providing 
information technology services, banking, and capital market, mortgage services, 
however now extended to include clinical trial services. Pharmaceutical organizations 
tend to contract with BPOs for their clinical trial services. The BPO contracts are long-
term in nature than in traditional offshore outsourcing contracts requiring business 
partners to remain focused on building and sustaining value-creating relationships (Lahiri 
& Kedia, 2009). One gap with BPO that remains is the lack of understanding their quality 
as an ongoing business partnership.  
Scholars suggested that the quality of ongoing business partnerships needs to be 
high to enable collaborating organizations to realize valuable outcomes (Lee, 2001). The 
partnership quality is how well the partnership delivery outcomes match the participants’ 
expectations. According to Lee, the current context of partnership quality refers to the 
perception of the extent of fulfillment of expected outcomes arising out of the inter-
organizational relationship between provider and client. Prior research (Lee, 2001) shows 
that partnership quality as a valuable relational resource allows providers to perceive 
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nature of their cooperative relationships with clients, as well as, encourage them to 
consider ways to enhance or strengthen the same in order to perform better. Lee 
suggested the knowledge might enable providers to gauge their ongoing partnerships on 
various parameters such as compatibility with policies and culture, sharing benefits and 
risks, business understanding, and dependability. In addition, if there is such an 
understanding, providers are in a position to enhance performance by escalating 
commitment, coordination, and trust, increasing flexibility in accommodating changes, 
and considering clients as business partners and not just customers of services (Lee, 
2001).  
One of the top destinations for BPOs is India. Dzever and Gupta (2012) agreed 
the BPO is extensively growing and one of the sought out BPO destination is India due to 
the observation of clients that the BPO industry in India people work 'when the rest of the 
country sleeps'. There is the majority of BPO in India accommodates and work the 
European and USA time frames. Therefore, meaning most BPO employees in India work 
the night shift or the graveyard shifts. 
Outsourcing key risk factors As the outsourcing trend continues to rise, it is 
important for the organization to consider potential risk factors that occur when 
outsourcing and the importance of having a risk framework before signing any contracts 
with outsourcing vendors or BPOs. Critical risk factors to a client are associated with 
financial, complexity, contract, execution, legal, planning and control, the organizational 
environment, scope and requirements, the user and team (Alaghehband, Rivard, Wu, & 
Goyette, 2011). One of the important risk-based decision-making factors would be the 
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regional location of the outsourcing organization. The more information the organization 
has on the outsourcing region's geopolitical instability and economic volatility the lower 
the risk (Holbrook, 2011).  
Gholami (2011) conducted a qualitative study to determine the critical risk factors 
when outsourcing IT projects. The results showed the five key risk factors are financial 
risks, technical risks (such as database, communication infrastructure, software risk, 
security, and licensing), managerial risk, behavioral risks, and legal and political risks 
(Gholami, 2011). One of the common mistakes that senior management make in the 
outsourcing business model is not having the understanding or having the knowledge of 
the risks, the right tools to handle the risks and developing an effective mitigation for the 
risks (Ghandi, 2011 & Gholami, 2011).  
One of the main reason organizations benefit from outsourcing is a reduction in 
cost, however when outsourcing processes to offshore location increases strategically 
risks as a result of vendor to clients deliberate actives (Gholami, 2011; Liu & Nagurney, 
2011). Organizations need to conduct a quality assessment as part of the determining 
factor in choosing the most appropriate vendor that the organization determines has the 
quality and the right equipment (Yu & Thomas, 2011). Ghandhi (2011); Gholami, 
(2011); He, Weeks, Buyske, et al.(2011); and Yu and Thomas, (2012) agreed when 
choosing a vendor for long-term business process a vendor assessments are key. 
Pharmaceutical organizations’ need a complete understanding of the vendor 
organizational structure, trading relationship, operational manager, general management 
practices, quality culture and understanding their financial for successful projects. The 
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most common vendor risks during a quality assessment are knowledge transfer, lack of 
active vendor management, incomplete contracting trust (Hamlen & Thuraisingham, 
2012).  
Organizational management’s awareness of offshoring BPO’s cultural risk factors 
that often occur with client/organization and vendor relationships (Holbrook, 2011; 
Mosher & Mainquist, 2011) can alleviate future problems. Culture plays a significant role 
when dealing with offshoring vendors. Communications, management style, 
understanding each other culture, gender issues, quality management, and team harmony 
are at risk if client and vendor have serious communication break (Holbrook, 2011). 
Quality of Clinical Trials 
With the developments of global markets quality has become the central focus. 
Previously, many companies have forgotten to include quality as part of their strategic 
objectives (Devpura, Garza–Reyes, Kumar, Rocha–Lona, & Soriano–Meier , 2014). 
However, now quality measurements and quality performance are the key focus of 
numerous companies in the global markets. A single case study conducted on a 
multinational Fortune 500 pharmaceutical company who has built a conceptional quality 
model in their strategic objectives to explore how quality model affects their processes 
(Devpura et al., 2014). The results showed a company who had a total quality 
management built into its model earlier showed greater global competition, advanced 
programs, and effective quality processes. In addition, European companies include the 
ISO 9000 criteria for a quality model and emphasis on the quality culture were the 
highest marked for their quality products (Devpura et al., 2014). When research 
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organization conduct clinical trials, it is important for them to adhere to good clinical 
practices. Adhering to these practices will help to avoid an audit finding from sponsor 
and health authority agencies (Karbwang, 2013).  
One major need for consumers is for a drug developed by the pharmaceutical 
organization to provide safe and effective therapeutic drugs to promote, cure, and treat 
diseases, as well as, health and prevention (Sasaki, McGibbon, Lee, Murray, & Pharr, 
2014). The pharmaceutical organization’s ability to consistently deliver these products 
declined in the last few years due to job losses, site closures, an increase of R&D costs, 
and productivity lags (Sasaki et al., 2014). Due to the decline, pharmaceutical 
organizations are finding alternate methods to produce consistently and deliver products 
with the decrease in cost. Pharmaceutical organizations are turning to CRO and BPO in 
Asia Pacific to reduce drug cost and approval. However, one question arises, what quality 
measures or steps are taken to provide a safe and effective drug? In recent years, both the 
FDA and European Medicines Agency (EMA), identifies the significant limitation of 
clinical trial oversight conducted by pharmaceutical organizations. An example of lack of 
clinical trial monitoring were illustrated when Johnson & Johnson, Pfizer, and ICON, 
received FDA 483 warning letter for significant lapses clinical trial oversight (Cerullo et 
al., 2014).  
India is similar to many other countries in the division of their medical regulatory 
structure between national and state authorities (Sackman & Kuchenreuther, 2014). The 
national authority for pharmaceutical regulations in India is known as The Drug 
Controller General of India (DCGI). The responsibility of the DCGI is to approve new 
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drugs, import drugs, and biological in selected category, approval of clinical trials and 
quality standards in the country. Sackman and Kuchenreuher agreed with FDA on the 
DCGI quality standards especially due to the citing quality-control problems ranging 
from data manipulation to sanitation. Due to concerns of the quality issues associated 
with the clinical trials the FDA and other regulatory bodies have increased inspections of 
Indian plants in response to the high amount of outsourced clinical trials being conducted. 
Pharmaceutical organizations are reassessing their Indian outsourced contracts with these 
plants and giving careful consideration to moving forward with developing new strategic 
partnerships (Sackman & Kuchenreuther, 2014). There are high concerns with data 
quality and data integrity, which impacts manufacturers' perception of India's clinical 
trials system. India became the most sought destination for the pharmaceutical 
organization for clinical trials due to the large and diverse patient pool, as well as, low 
drug trial costs makes the country an attractive. However, India has recently seen 
increased number of clinical trials fall dramatically due to allegations of noncompliance 
to protocols and organizations taking advantage of disadvantaged patients (Sackman & 
Kuchenreuther, 2014). Hanfield and Gosh (2004) and Sackman and Kuchenreuther  
agreed that due to noncompliance response manufacturers are forcing to either to move 
their trials to another country or encounter significant delays in clinical trial approval, 
which is ultimately holding their organizations back.  
For clinical trials to have the highest quality, it must adhere to good clinical 
practice (Cerullo et al., 2014; Handfield & Ghosh, 1994; Johnson & Gupta, 2014; 
Sackman & Kuchenreuther, 2014). GCP is defined as an international scientific and 
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ethical quality standard for conducting, designing, recording and reporting trials that 
involve the participation of human subjects (ICH, 2015). According to ICH, clinical trials 
must be compliant with GCP guidelines to ensure the protection of the rights, safety, and 
well-being of the research trial subjects, as well as, ensuring data integrity. The principal 
objective of the GCP guideline is to provide a unified standard for current good clinical 
practices amongst the European Union (EU), United States, and Japan to have quality 
standards and mutual acceptance of clinical data by the regulatory federal agencies within 
their jurisdictions (ICH, 2015).  
Adherence to GCP is the essential quality criterion for conducting clinical trials. 
The GCP standard practice applies to all parts of the clinical trial process. Pharmaceutical 
or any research and development organizations that do clinical research needs to build 
GCP requirements into their clinical trial processes to ensure quality in a clinical trial 
(ICH, 2015; Johnson & Gupta, 2013). Under the GCP guidelines, the quality of the 
clinical trial is a continuous sequence, which commences with designing, conducting, 
recording, and reporting of the clinical trials (Johnson & Gupta, 2013). Compliant with 
the GCP quality standard throughout the clinical trial conduct guarantees that the data 
reporting analysis results are credible and reliable, as well as, ensures the rights, safety, 
and well-being of the human subjects. 
Consequently, even though there is no change to ICH GCP (2015) guidelines over 
the years, adherence to these principles have become more difficult to attain, due to the 
changing scenery of conducting the clinical trials (Johnson & Gupta, 2013). Lad and 
Dahl (2013) shared a similar concern for the role quality plays in clinical trials and 
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processes. Despite the acknowledgment of importance that is placed on quality assurance 
in the clinical research process and clinical trials, there is still a high-level concern for 
quality assurance program implementation in foreign academic teaching hospitals or a 
similar institution. Even though, the fact that quality assurance is expected in such 
programs that certify and accredit Institutional Review Boards (IRBs), very little is 
known about the role of the IRB in programs of clinical research quality assurance. In the 
IRB programs, clinical quality assurance needs to be defined, and processes placed in 
achieving quality assurance (Lad & Dahl, 2013). According to Lad and Dahl, essential 
elements of the quality assurance program are continuous education and training at site 
level, as well as, auditing and monitoring program, which reinforces the understanding 
and knowledge of quality assurance.  
In order to measure the quality of a clinical trial, an audit needs to be conducted to 
ensure adherence to the clinical protocol, sponsors' clinical trial process, and clinical 
regulations. One of the quality breakdowns in a clinical trial process is the auditing of the 
informed consent (Lad & Dahl, 2014a). An informed consent is one of the essential 
clinical documents for clinical trials and can be defined as documentation, which informs 
the clinical trial participant about the clinical trial and the risks and benefits associated 
with the clinical trial, as well as any unforeseen risks associated with the clinical trial. 
Informed consent emphasizes the clinical trial participants’ rights and volunteer 
participation in the clinical trial (Lad & Dahl, 2014b). An audit of the informed consent 
should be conducted to ensure adherence to the federal regulations requirement. The 
informed consent is a signed documentation from the voluntary participants to participate 
43 
 
in the clinical trial process and documents the conversation between the sponsor and 
voluntary participant in the clinical trial. Sponsor’s conducting audit of the informed 
consent will help to ensure better alignment to the clinical protocol and federal regulation 
and will help ensure less scrutiny of regulatory agency inspections and IRB. 
Clinical Trial Process Improvement  
The data from this study might impact social change by providing awareness, 
knowledge, and risks associated with quality breakdowns when the pharmaceutical 
industry is outsourcing R&D. Outsourcing R&D caused negative relationships with 
pharmaceutical companies employees with the outsourcing employees (Mendivil, 2012). 
Due to outsourcing, internal resources are being laid off; morale is decreasing, and 
strained resources. The research data may provide insight to the leaders the effects it has 
on their internal employees and how to improve and build a better relationship with 
internal resources and outsourcing associates (Mendivil, 2012). Furthermore, it may also 
provide ways to enhance business practices and the conduct of an outsourced clinical trial 
quality to bring the safest most effective medicinal product to patients faster.  
According to Paul (in press), there is an extremely competitive race for a 
pharmaceutical organization to bring the first new drug therapy to the market. The 
pharmaceutical organizations’ face increasing challenges such as drug cost pressures, 
difficulties in obtaining patient recruitment, and drug target population. Even when the 
pharmaceutical industry meets its challenges, there is always an unexpected regulatory 
finding of the testing procedures and quality of the trial, which can derail an entire 
clinical program. The last decade global regulatory agencies have been placing increased 
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scrutiny on clinical data quality. Due to the increased regulatory scrutiny, there is a 
stimulus for the development of more effective and consistent quality management 
systems (Paul, in press). 
Jones, Parast, and Adams (2010) have a similar view to Mendivil (2012) and Paul 
(in press) however, a different approach to how to improve process improvements while 
organizations are facing challenges. Jones, Parast, and Adams  argued that process 
improvement initiatives do not always provide the best results; however, organizations 
need to frame it within the systematic process improvement structure. Emphasis on 
elements such framed within a systematic process improvement structure. Elements 
vision, skills, resources, action plans, and incentives are necessities to have an effective 
six-sigma implementation (Jones, Parast, & Adams, 2010). A deficiency in any of the 
above stages of process improvement will have an adverse effect on the desired outcome 
of any project. Similarly, Wong, Tseng, and Tan (2014) agreed to boost organizations’ 
performance they need to configure business process model in order for the team 
performance to improve continuously. 
Transition  
The purpose of this study was to explore one pharmaceutical organization’s 
clinical quality assurance management team’s knowledge and experience of the quality 
management system breaks when outsourcing clinical trials to Asia Pacific. The in-depth 
description data lead to highly successful outsourced clinical trials. In the literature 
review, I discussed various components of the general systems theory, quality 
management system, clinical trials processes and regulations, outsourced clinical trials, 
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current challenges that pharmaceutical organizations are facing and discuss the decision 
to move to an outsourcing model, as well as, discussing the risks and benefits of 
outsourcing clinical trial to the top outsourcing destination Asia Pacific.  
In the Section 2, I will discuss in detail the doctoral study. The rationale for why I 
chose the qualitative case study design and the importance of the role of the researcher, 
the inclusion and exclusion criteria of the participants for the study, the population and 
sampling, the data collection techniques and data analysis. A detailed discussion in each 
of the above sections will explore pharmaceutical leaders’ procedural policies leading to 
successful outsourced clinical trials. In Section 3, I will describe the application to 
practice and to implement change. In addition, I will provide a detail description of (a) 
overview of the study, (b) presentation of the findings, (c) application to professional 
practice, (d) recommendations for action, (e) recommendation for the further research, (f) 
reflections, and (g) study conclusions. 
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Section 2: The Project 
Section 1 of this doctoral study presented research information on various 
pharmaceutical challenges such as regulatory laws, patent expiries, the high cost of 
developing drugs in research, and development pushing pharmaceutical leaders to 
outsource clinical trials to developing countries in an attempt to be more cost effective. In 
Section 1, I explored the current problem that exists when clinical trials are being 
outsourced to developing countries. In Section 2, I will provide a detailed description of 
the research method and design of the study. Furthermore, Section 2 contains (a) 
researcher role, (b) the participants for the study, (c) the research method and design, (d) 
population sampling, (e) ethical research, (f) data collection and organization techniques, 
(g) data analysis, and (h) the reliability and validity of the study. 
Purpose Statement 
The purpose of this qualitative case study was to explore strategies clinical quality 
assurance managers use to avoid a breakdown in quality with outsourced clinical trials in 
Asia-Pacific countries. The data collected from clinical quality assurance managers 
provided information on why breaks occur or do not occur within the total quality 
management system after agreed quality contracts to reduce the risk in clinical trials. 
Participants came from the clinical research and development sector of one 
pharmaceutical organization located in the Northeast region of the United States. The 
information provided by clinical quality assurance managers may contribute to social 
change through the creation of strategies to avoid quality breakdowns with outsourced 
clinical trials.  
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Role of the Researcher 
My role as the researcher for this qualitative case study was to gain access to the 
investigational research site and gain the trust of my research participants (Hancock & 
Algozzine, 2011; Marshall & Rossman, 2014) to gather good data.. My role was to 
isolate and define the qualitative categories and phenomenon. According to Fink (2000) 
and Hancock and Algozzine, the researcher needs to understand the research being 
studied. In order for me to understand the research, I answered the question of what in the 
research is going to be  studied, why it is going to be studied, and how it is going to be 
studied. The answers to these questions will drive what will become the background in 
the study analysis and reporting.  
I have 15 years of experience as a global development quality manager   both in 
clinical trials and manufacturing sites. The study participants were quality assurance 
colleagues; however, they were from different line functions within the clinical quality 
assurance organization. Line functions within clinical quality assurance include but are 
not limited to eClinical, outsourcing, audit, clinical, compliance, training, vendor, drug 
regulatory, and pharmacovigilance.  As a global quality manager, I am trained and 
frequently certified on clinical trial ethics and human subjects’ rights. In addition, I 
completed the National Institute of Health (NIH) web-based training course Protecting 
Human Research Participants, exhibiting my knowledge of ethical behavior and the 
research process (Appendix E). My role as a researcher was also to recognize my 
personal bias and bias to the research. My role within the organization is quality 
assurance manager. Because of my role, I mitigated the effects of my prejudice and bias 
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to ensure impartiality to the research conclusions (Hancock & Algozzine, 2011). I used 
methodological triangulation from different sources to increase the reliability of the data 
(Barratt, Choi, & Li, 2011). The use of methodological triangulation minimized bias from 
me as well as the participants. Furthermore, I used member checking of interview 
transcripts to minimize bias and help identify data analysis themes and data results 
(Onwuegbuzie, Leech, & Collins, 2010).  
For this study, I was the data collection instrument. I used an interview protocol to 
manage the available time of the interview session and focus on the 10 interview 
questions. I took detailed notes during the individual semistructured interviews in an 
appropriate private interview setting (Hancock & Algozzine, 2011). I transcribed the 
interviews verbatim into a Word document, analyzed and coded the data, as well as, 
verified and reported the data (Fink, 2000; Hancock & Algozzine, 2011). To ensure the 
ethical and legal requirements of research were followed, I collected the participants’ 
signed informed consent forms prior to conducting the interviews (Hancock & Algozzine, 
2011).  
Participants 
Suri (2011) noted the researcher choosing participants for semistructured 
interviews must establish a sampling strategy conceptually aligned with the research 
purpose, which adequately addresses the research design. The criteria of the research 
participants included a minimum of 5 years of experience within the clinical quality 
assurance organization. Only clinical quality assurance managers who had experience 
with Asia Pacific outsourced clinical trials were included. Participants were at least 18 
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years of age or up to 65 years of age to enter the study. The strategy to gain access to the 
purposive sample of the 15 clinical quality assurance managers was from an invitation 
via e-mail or through teleconference meeting invitations (Appendix A). I followed up 
with a phone call or e-mail to answer any questions or concerns the participants may have 
about the study. After participants gave confirmation to volunteer for the study, I sent an 
informed consent form (Appendix B). Once I received the signed informed consent, I 
asked participants if they would like to have a face-to-face interview, phone interview, or 
e-mail questionnaire. The face-to-face interview was the ideal method; however, alternate 
methods were used if participants were unable to make the face-to-face interviews. 
Building a relationship with the participants helps the researcher gain access to the data 
(Patton, 2005). 
To establish a working relationship involving trust, open communication, and 
positive interaction with the clinical quality assurance participants, I drew upon my 
interpersonal skills. It was critical for me to build trust; be patient; be a thoughtful, 
sensitive, empathetic listener; and be respectful of the participants (Marshall & Rossman, 
2014). The positive work relationships created a safe and comfortable atmosphere for the 
participants during the interview process. The data collected from clinical quality 
assurance managers provided information on why quality breaks occur in outsourced 
clinical trials in Asia Pacific after agreed quality contracts. 
Research Method and Design  
In this section, I expand upon the information presented in Section 1 on the 
research method and design. I describe various research methods and designs while 
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justifying why one particular research method and design was chosen. I justify why the 
qualitative case study was the best-suited research method and design to answer my 
research question: What strategies do clinical quality assurance managers use to avoid a 
breakdown in quality with outsourced clinical trials in Asia-Pacific countries?  
Research Method 
There are three research methods a researcher chooses from: qualitative, 
quantitative, and mixed methods. In a qualitative study, the researcher’s specific interest 
is trying to uncover the meaning of the phenomenon of those involved (Merriam, 2014). 
Marshall and Rossman (2014) and Merriam noted that qualitative studies are used for 
descriptive or exploratory research that focuses on participants’ lived experiences and 
settings. Bartkowiak (2012), Marshall and Rossman, Merriam , Patton (2005), and 
Thomas and Magilvy (2011) agreed the key benefit of qualitative research is to 
understand how people interpret their experiences through various research designs. To 
understand the reasons why breaks occur or do not occur in quality management system 
Asia-Pacific outsourced clinical trials, in-depth description from clinical quality 
assurance managers was needed to understand the phenomenon. Merriam noted there are 
four characteristics that identify qualitative research methodology: (a) the primary 
instrument for data collection and data analysis is the researcher, (b) the product is 
descriptive, (c) the focus is on meaning, process, and understanding, and (d) the process 
is inductive. Maxwell (2012) emphasized that when a researcher possesses any of the 
following five intellectual goals for the study, the best methodology is qualitative: (a) 
generating new grounded theories, (b) identifying unanticipated phenomena and 
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influences, (c) understanding the process by which actions and events take place, (d) 
developing casual explanations, and (e) understanding the participant's perceptive. 
Similarly, Hsuan and Mahnke (2011) recommended qualitative research for process 
inquiries to seek understanding of how pharmaceutical managers manage the outsourcing 
R&D and address gaps in the process. Kurkkio, Frishammar, and Lichtenthaler (2011) 
noted that qualitative research is used to seek information on new process developments 
when little if any information is given in prior studies. Hunt (2011) noted that if a 
researcher uses the following five methods within his or her research, then the research is 
qualitative: (a) seeks answers to questions, (b) collects evidence, (c) systematically uses a 
predefined set of procedures to answer the question, (d) produces findings that were not 
determined in advance, and (e) presents findings that are applicable beyond the 
immediate boundaries of the study. Bernard (2013) suggested that a qualitative method 
was appropriate to gain insight from pharmaceutical R&D leadership on how outsourcing 
clinical trials to Asia Pacific was affecting the overall quality of the trials and how one 
could improve quality business practices. The optimal way of collecting data was through 
face-to-face semistructured interviews or telephone interviews that aligned with the 
qualitative research method of collecting data and the researcher being the instrument to 
collect data. The qualitative research method allowed for more flexibility, and interview 
questions were open ended.  
For quantitative research, there are specific research questions that are answered 
by proposition tests or hypotheses being examined (Marshall & Rossman, 2014). 
Merriam (2014) emphasized the focus of quantitative research is how much or how 
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many. Bernard (2013), Johnson and Christensen (2008), and Oleinik (2011) noted the 
goals of the investigation for the quantitative methodology are confirmation, description, 
prediction, control, and hypothesis testing. Quantitative methodology was not appropriate 
for this study because there were no numeric data being collected or hypotheses being 
tested. To gain insight into quality trial processes from the R&D participants, open-ended 
questions were needed; quantitative research relies on fixed response options. 
Quantitative research does not provide flexibility because questions are closed and 
participants’ responses do not influence how or which questions are asked next.  
The final methodology is mixed methods, which is used when a researcher 
collects both quantitative and qualitative data from either a series of studies or a single 
study (Cameron, 2011; Mengshoel, 2012; Tashakkori & Teddlie, 2010). The mixed 
methods approach helps the researcher determine whether an intervention works or why 
it does not work, as well as how it delivers (Farquhar, Ewing, & Booth, 2011). According 
to Farquhar et al., mixed-methods are particularly advantageous in research when the 
process evaluation is challenging and most of the interventions are challenging. Cameron, 
Farquhar et al., Onwuegbuzie et al. (2013), and Tashakkori and Teddlie  noted that mixed 
methods would not be appropriate for gaining insight into pharmaceutical leadership 
knowledge of the clinical trial process for outsourcing clinical trials.  
Research Design 
Five primary research designs exist in qualitative research:  phenomenological, 
grounded theory, ethnographic, narrative, and case study. In order to explore the clinical 
quality assurance managers’ knowledge of quality management system breakdowns in 
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the outsourced clinical trial in Asia Pacific, I used a single case study. A single case study 
was also preferred by previous researchers examining pharmaceutical R&D leadership’s 
knowledge of management and barriers within the internal R&D departments to enhance 
applications of the knowledge management team (Lilleoere & Hansen, 2011). Similarly, 
Zhang, Pawar, Shah, and Mehta (2013) conducted a case study to investigate how to 
assess outsourced work and manage outsourcing relationships in the pharmaceutical 
industry. Jensen (2012) recommended case studies as the best approach for the offshore 
outsourcing process to provide a detailed description of influential factors of the process.  
According to Yin (2014), a case study is an empirical inquiry conducted to 
investigate a contemporary phenomenon in depth and within a real-world context, 
especially when the boundaries between the phenomenon and context may not be 
apparent. The case study was the preferred method because the central research question 
was what question, the focus of the study was a contemporary phenomenon, and I had no 
control over behavioral events (Yin, 2014). In addition, Yin noted that multiple sources 
of data in the case study allow a researcher to address a broader range of historical and 
behavioral issues. In this single case study method, sources of data such as 
documentation, archival records, responses to semistructured interviews, and direct 
observations were used (Yin, 2014). I continued to interview the clinical quality 
managers until data saturation was evident. Data became saturated when I determined the 
reviewed data no longer had the new experience, perspective, and information. 
Chikweche and Fletcher (2012) noted that data is statured when there is no   new coding, 
themes, and can  replicate the results .The three classifications of case studies are 
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descriptive, exploratory, and explanatory (Yin, 2014). In this case study, I chose 
descriptive because the goal of the research was to provide a rich description of quality 
management system breakdowns of clinical trials in developing Asia-Pacific countries 
(Denzin & Lincoln, 2011; Yin, 2014).  
I excluded the narrative research design because the focus of this study was not on 
the lived experience of one or two individuals, and data collection was not through 
collections of stories or experiences (Goulding, 2005). Additionally, the 
phenomenological design was not chosen because the goal of the research did not have an 
emphasis on the phenomenon explored or any individual or group who experienced the 
common phenomenon (Merriam, 2014; Moustakas, 1994). Hays and Wood (2011) 
suggested a grounded theory would not be appropriate for my study because the focus of 
the research was not to develop a theory, and the focus of the research was not a 
particular action that occurred over time. Finally, the ethnographic design was not 
appropriate because my research aim was not to focus on a culture-sharing group 
(Goulding, 2005). 
Population and Sampling 
The participants for this study were 15 clinical quality assurance managers 
working in the R&D clinical sector in one pharmaceutical organization located in 
Northeast region of United States of America. The 15 participants who met all the 
eligibility criteria entered the study. The participant’s age was a minimum of 18 years to 
65 years of age, working in or previous worked in clinical quality assurance organization 
of the pharmaceutical organization. Participants will have at least 5 years of experience 
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with clinical trials and have experience working with outsourcing organizations or 
business process organizations. 
The sampling method used for this qualitative case study is purposeful. Merriam 
(2014), as well as, Suri (2011) noted a purposeful sample should be at least 15 
participants to gain in-depth, rich data. Additionally, Boeije (2010) recommended a 
sample size of at least 15 participants would be suitable or until data saturation. The 
sample of the research participant occurs purposely to gain the knowledge of the varied 
experience of the participant's knowledge of quality management system breaks for 
outsourcing clinical trials. The research participants were clinical quality assurance 
managers who are contributing to quality and vendor oversight of the clinical trials on a 
daily basis. Part of their job description is to adhere to regulations and standard operating 
processes, as well as, handling quality breakdowns in the system, process, and clinical 
trials. Clinical quality assurance managers mitigate risks of the clinical trials, conduct risk 
and gap assessments of the clinical trial processes, participate in sponsored or federal 
inspections, and are the point of the contact for outsourced clinical trials in Asia Pacific 
when there are issues, concerns, or questions. Clinical quality assurance participants have 
the essential information needed for this research study.  
Patton (2005) noted that power and logic of purposeful the sample come from 
selecting information risk cases for study in-depth. The purposive sample approaches of 
15 participants were face-to-face semistructured interviews with open-end research 
question, which allowed the participants’ knowledge of outsourcing clinical trial process 
phenomenon (Bartkowiak, 2012; Suri, 2011). Yin (2014) noted that conducting 
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semistructured interviews will bring forth insight and help the focus stay targeted on the 
study topic. The open-ended interview questions provided a guide conversation between 
the participants and myself, as well as, allowed the interviewees to build on their ideas, 
concepts, and thoughts. Furthermore, the semistructured interviews allowed me to follow 
up with questions through member checking to expand on their experiences. The 
interviews took place in the private setting environment such as a private and isolated 
meeting room within the pharmaceutical organization. 
Ethical Research 
Ethical research requires qualitative researchers to show they are trustworthy, 
reliable, and credible (Patton, 2002). I submitted the research study proposal and 
informed consent to the Walden University's Institutional Review Broad (IRB) for review 
and approval prior to collecting any data on participants. The informed consent provided 
information to the research participants: (a) the nature of this case study; (b) inform him 
or her of their rights that no harm, coercion, or deception will come to them in the study; 
(c) protection of their privacy and confidentiality; (d) protect the vulnerable groups; 
and(e) selecting participant equitably (Abramson & Abramson, 2011; Yin, 2014). Each of 
the research participants received an informed consent (Appendix A) and given ample 
time to read and determine if they may want to participate in the study. A participants’ 
signed informed consent was collected before entering the study. A copy of the signed 
informed consent was given to the participant for their records. Furthermore, this initiated 
the enrollment of the participants in the study.  
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The study did not involve participants who are particularly vulnerable or unable to 
give informed consent. To minimize risk to the human subjects, I utilized consistent 
procedures, sound research design, and avoided unnecessary risks to subjects (FDA 
Regulations, 2015). The risks to subjects were reasonable in relation to anticipated 
benefits, if any, to subjects, and the importance of the knowledge that is expected to 
result (FDA Regulations, 2015). The research participants voluntarily participated in the 
study and could withdraw from the study at any time or choose not to answer an 
interview question if they are uncomfortable to do so. The participant could withdraw by 
contacting me via e-mail or telephone if they are no longer interested in participating in 
the research study. The participants could withdraw from the study at any time. All data 
collected from participants who have withdrawn are destroyed or deleted from the 
database, and any written documents are destroyed. To protect the identity of the study 
participants, I assigned a code CQA1-CQA15 to each participant. To protect the identity 
of the pharmaceutical organization, I assigned a code name XYZ pharmaceutical 
organization. In order to enter the study, the participants must be at least 18 to 65 years of 
age, as well as, mentally stable (FDA Regulations, 2015). During the study, there were no 
compensations, gifts, reimbursements, and free services for participation in this research 
study (FDA Regulations, 2015). 
In order to protect the rights of the participant’s data, it was maintained in safe, 
secure locked storage and archived for 5 years. Participants’ personal information was 
stored on my personal computer files and on a memory stick. Participants’ data were 
protected by encrypted, and password protected computer files and labeled by the 
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participants’ coded name. After 5 years, data will be destroyed through shredding of 
documentation and deleting data from the computer files. I signed a confidentiality 
agreement (located in Apendix D) due to the highly confidential information received 
from the research participants.. 
Data Collection Instruments 
  In this single case study, I am the primary data collection instrument through face-
to-face, or telephone semistructured interviews or e-mail interviews. Yin (2014) noted 
one of the most key sources of case study evidence is the interview. Chenail (2011) and 
Denzin and Lincoln (2011) recommended that in conducting qualitative research the 
researcher is the key person who is obtaining the participant's data and, therefore, the 
instrument. I conducted semistructured interviews to allow both myself and the 
participants to have in-depth interviews through a conversation style and build a level of 
comfort and familiarity to allow for a sustainable, meaningful interview (Barratt, 2012). 
In addition, Chenail summarized that when a researcher facilitates a conversational style 
that a context is created where the participants feel comfort and share rich data through 
their lived experiences. Cook (2012) and Barratt, (2012) recommended that online 
interviews provide participants more flexibility and time to answers questions Online 
interviews also provided extra confidentiality of the sensitive topic that most participants 
may not feel comfortable in a face-to-face environment (Markham, 2008). Gill, Stewart, 
Treasure, and Chadwick (2008) were also in alignment that semistructured interviews 
was the best approach because it explored the individual experiences, views, and beliefs 
on specific matters such as the quality of the outsourcing clinical trial processes. 
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Interviews were the most appropriate method of collecting data in a qualitative case study 
because they provided a deeper understanding of the social phenomena and can be used 
to collect detailed insights about the quality of the outsourced clinical trial processes from 
the R&D participants (Barratt, 2012; Chenail, 2012; & Gill et al., 2008).  
The processes, I followed for collecting data from the participants: (a) study 
invitation and informed consent to the research participant Appendix C and Appendix A; 
(b) research participant signed the informed consent to participate in the research study; 
(c) both the research participant and me scheduled an appropriate time and date for the 
interview; (d) conduct the interview in a confidential interview setting; (e) for research 
participants who did not want a face-to-face interview, they completed online 
questionnaire and returned to the researcher within a few days; and (f) follow up 
meetings were also scheduled on any interview transcripts that need further clarification. 
The semistructured interview consisted of 10 construct study specific sets of open-ended 
questions located in Appendix B. The data collection instrument was critical in 
identifying themes in data collection. Since, I am the data collection instrument all 
participants’ data coded by experiences and perception from the interviews.  
Yin (2014) recommended establishing quality tests in qualitative case study 
research are reliability and validity. Bernard (2013) defined validity is the trustworthiness 
and accuracy of the instrument. In this case study, I (a) reviewed interview questions to 
ensure interview questions meet the aim of the research study, (b) the questions were 
clear and concise for the research participant to understand, (c) prepare for the interview 
sessions to provide for consistency of all R&D participants, and (d) utilize the pyramid of 
60 
 
evidence from peer-reviewed research and expert opinion is the basis for ensuring 
reliability and validity of the data collection instrument. In order to enhance data through 
reliability, I transcribed my interview notes verbatim into a Word document. I utilized 
NVivo 10 software to generate themes and patterns from the interview transcripts (Gill et 
al., 2008). At the end of each interview session, I conducted a member check by e-
mailing each research participant the interview transcript to ensure the information 
transcribed correctly. In addition, follow up interviews questions were asked if interview 
answers are unclear. Merriam (2014) and Bernard (2013) recommended researchers 
organize data through themes, patterns, and concepts for descriptive data analysis coding. 
According to Yin (2014), process check improves the instrument, questions, and 
measures of the instrument. I conducted a process check after interviewing two  research 
participants to improve the interview questions or methods. 
Data Collection Technique 
The data collection techniques for this single case study were a face-to-face 
semistructured interview, telephone interviews, or e-mail questionnaire; and 
documentation from literature reviews, XYZ pharmaceutical organization’s quality 
reports, and federal government reports. The advantages with documentation are stability, 
unobtrusive, specific, and broad (Yin, 2014) and the advantages of interviews are it is 
targeted and insightful (Gill et al., 2008; Yin, 2014; Merriam 2014). Yin noted one of the 
most significant utilization of documentation is to corroborate and augment the evidence 
from multiple sources. The semistructured interviews consisted of 10 opened ended 
research questions to collect information from the research participants of the quality of 
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clinical outsourced trial processes located in Appendix C. Merriam  summarized the 
importance for a researcher to conduct interviews is to obtain a kind of information 
through a conversation with purpose (Patton, 2005). In addition, Barratt (2012); Chenail; 
and Merriam  noted that semistructured interviews provide flexibility of the research 
questions, specific data required from all of the participants, interview guide consist of 
mix of structure questions, and majority list of research questions for the interview are to 
be explored. Face-to-face semistructured interviews are preferred, however due to the 
multiple locations of the R&D clinical sites within the XYZ pharmaceutical organization 
alternative method of telephone and e-mail questionnaire is given to allow for the 
participation flexibility. Cook (2012) and Barratt (2012) recommended online interviews 
provided participants more flexibility and time to answers questionnaire. It also provided 
extra confidentiality of the sensitive topic that most participants may not feel comfortable 
in a face-to-face environment (Markham, 2008). Even though there are strengths in 
conducting interviews and collecting data from documentation there are also associated 
disadvantages such as retrieve ability of documentation, documentation access, response 
bias for interview questions, reflexivity, and participants uncomfortable to answer 
questions on sensitive topics (Yin, 2014).  
After the completion of the first two interviews, a process review check of 
research questions and responses to ensure the aim of the research (Yin, 2014). After 
interviews were transcribed, the text is downloaded to NVivo 10 software. Once the data 
was transcribed verbatim, a member check occurred. The participants’ reviewed 
transcripts for accuracy. 
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Data Organization Technique 
All data collected from interviews, informed consents, interview transcriptions, 
and documentation are stored on my locked password protected the computer. In 
addition, to avoid data from being lost or damaged, data was also stored on a password 
protected memory stick. Merriam (2014) and Maxwell (2012) recommended for large 
amount of data collection from field notes, documentation, and interview, the qualitative 
researcher needs to find a structure to organize data. While Yin (2014) noted the case 
study database should be orderly where the data is retrievable. Data collected from 
documentation and interviews labeled and filed in the main study folder quality data file 
and the subfolder were labeled with participant's coded name clinical quality assurance 
participant (CQA) 1-15 where all corresponding informed consents, transcripts, and hand 
written notes were stored and filed. All raw data collected from this study in a locked 
password protective storage container for five years. After 5 years, I will destroy data by 
deleting all data from memory disk and the password protective laptop. 
Data Analysis 
Data analysis involves immersion of the data, organizing the data, generating 
themes and patterns, coding the data, integrating and summarizing the information that 
the researcher has read and observed, thus providing meaning to the data (Marshall & 
Rossman, 2014). What strategies do clinical quality assurance managers use to avoid a 
breakdown in quality with outsourced clinical trials  in Asia-Pacific countries? 
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1. How do clinical quality assurance managers regulate the clinical quality 
management systems and adapt to changes when trials are outsourced to 
Asia Pacific?  
2. How do clinical quality assurance managers ensure that clinical trial 
vendors adapt to the changes in the environment and process negative 
feedback?  
3. What actions are taken by clinical quality assurance managers to ensure 
outsourced clinical trial vendors are following the agreed contracts?  
4. What strategies do clinical quality assurance managers employ to ensure 
compliance from an outsourced clinical trial vendor after an agreed quality 
contract? 
5. What are some risks and benefits associated with clinical trials when 
outsourced to Asia Pacific? 
6. How do clinical quality assurance managers build successful relationships 
with clinical trial vendors and sustain those relationships with an ever-
changing outsourcing business model?  
7. How do clinical quality assurance managers ensure standard methods of 
communication of newly released standard operating processes, 
regulations, systems, and tools to outsourced clinical trial vendors?  
8. In a 1-year time frame, how often do clinical quality assurance managers 
and outsourcing vendors reassess quality agreements, contracts, processes, 
and potential gaps? 
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9. What strategies have/have not worked with outsourcing clinical trials to 
ensure the highest quality of the clinical trial?  
10. Is there any additional information you would like add that I may not have 
addressed by the interview questions? 
Denzin and Lincoln (2011) noted the use of triangulation in qualitative research 
secures in-depth understanding of the central research question. In addition, Marshall and 
Rossman (2014); Oleinik (2011) and Yin (2014) asserted that methodological 
triangulation strengthens the quality of the case study because multiple sources provide 
multiple measures of the same phenomenon. The use of methodological triangulations 
from various sources such as documentation from XYZ pharmaceutical organizations’ 
quality reports and federal agencies reports and interviews allowed me to form an 
understanding of the quality management system breaks (Jensen, 2012). Once the data 
was collected from the interviews, I transcribed interview notes verbatim to a Word 
documents; the NVivo 10 software assisted with identifying, sorting, and coding of 
themes and pattern analysis. Yin  supported computer-assisted tools such as NVivo 
software because it is a tool to help guide researchers to categorize and code large 
amounts of data. Denzin and Lincoln  noted NVivo software assists researcher in data 
coding, content analysis, and helps to identify themes and patterns. Yin  noted the 
conceptual framework assists in data analysis in a case study, which provided structure to 
analyze the research question. One of the strengths of using the case study is the diverse 
data sources through triangulation, which provided an accurate understanding of the 
phenomena. Hence, the use of reflexivity and triangulation improved my understanding 
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of the complex nature of the phenomenon, as well as, allowing me to explore the 
subjective experiences of the quality assurance managers.  
The conceptual framework for this study developed from von Bertalanffy’s 
(1968) general systems theory. For outsourced clinical trials to have the utmost quality, 
the clinical trials must adhere to standard operating processes, quality management 
system, and federal and local regulations. In order to maintain the highest quality 
standards, the pharmaceutical organization must have a robust quality management 
system. Laszlo and Kippner (1998) noted the concept of the general systems theory is it 
integrates with complex component relationships and identifies boundary maintaining 
processes or entities. Senge et al. (2011) noted leaders are seeking to understand how to 
deal with information and how to utilize it for sustainable innovation. In order for the 
pharmaceutical organization to enhance the outsourcing quality environment, 
organizations’ leaders should  integrate compliance or beyond compliance to their 
business environment.  
Reliability and Validity 
Reliability 
The main concern in a qualitative research study is to produce reliable and valid 
results (Merriam, 2014). Yin (2014) defined reliability as demonstrating data collection 
procedures repeats with same results. Wahyuni (2012) compared reliability to the 
dependability of the qualitative research through operational processes. In order for 
another researcher, to produce reliable and valid results they must follow the same 
operational procedures to produce the same finding and conclusions. To ensure 
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dependability, prior to the interview I reviewed interview questions and prepared for the 
interview to ensure reliability. Merriam (2014) noted in a qualitative research study, a 
human instrument can make the study more reliable by training and practicing. Seidman 
(2012) noted recordings enhance reliability by preserving the participant words, and it 
becomes the source data, and researcher should ensure the quality checks are made to the 
recorded prior to interviews. A list of follow-up questions is created from interview 
transcripts to allow further clarity on participants’ responses. To enhance the interview 
process, I conducted a transcript review check after the first three interviews to verify 
interview accuracy (Yin, 2014). Therefore, to ensure reliability for the study, I utilized 
member checking for (a)notes and data,  (b) audit interview questions for consistency, (c) 
review interview transcripts for any errors, (d) practice my interview skills, and (e) 
document all data collection procedures. In addition, I demonstrated the credibility of this 
single case study design by achieving data saturation through credible processes 
(Houghton, Casey, Shaw, & Murphy, 2013). 
Validity 
In this qualitative single case study, I used both internal and external validity tests 
to establish quality in case study research (Yin, 2014). For internal validity is when the 
researcher interpretation is correct when there is no direct observation (Yin, 2014). In the 
external validity, domains are established in order for the results to generalize (Yin, 
2014). Maxwell (2012) described validity as the creditability of the description, 
conclusion, interpretation, and explanation. Merriam (2014) noted achieving credibility in 
qualitative research studies can be achieved through the personal experience phenomenon 
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to obtain thick, rich, descriptions and in-depth participant interviews to receive rich data. 
To ensure internal validity/credibility, I transcribed semistructured interviews verbatim 
and reviewed transcripts for any errors, and used follow-up questions for clarity and 
member checking. In addition, all interview transcripts will be e-mailed to the research 
participants for review to ensure data accuracy. I used the NVivo 10 software for theme 
and pattern analysis. In addition, member checking ensured transcript review; peer 
debriefings were conducted after to discuss gathered data and used methodological 
triangulation by collecting data from multiple sources (Yin, 2014). Marshall and  
Rossman (2014) recommended addressing any concerns with the validity the researcher 
constructs to capture through credibility, transferability, dependability, and 
confirmability.  
To establish external validity for this qualitative single case study, I used the 
methodological triangulation method (Yin, 2014). The data collected from interview 
transcripts and documentation such as field notes, government reports, and xyz 
pharmaceutical organization's quality reports will provide validity. Maxwell (2012) noted 
triangulation can reduce the risks of bias and strengthen the validity. Furthermore, Yin  
noted the researchers who utilize using multiple sources of evidence in case studies are 
rated highly in terms of overall quality. Marshall and Rossman (2014) also recommended 
triangulation and member check as the strategy for internal validity in a qualitative 
research study. While Trotter (2012) noted in qualitative research creditability equates to 
internal validity. To establish dependability, credibility, and transferability, I triangulated 
data from documents and interviews; use member checking as participants review their 
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interview transcripts and develop rich, thick descriptive themes and pattern (Harper & 
Cole, 2012) through NVivo 10 software. Transferability of this study is by referencing 
the research sources to allow future researchers, as well as, the readers to determine 
whether the information transfers to enhance clinical business practices 
(Nawakitphaitoon, 2014). Therefore, to improve the credibility or trustworthiness of the 
data and quality, I used semistructured interviews, member checking, and researchers’ 
notes.  
Transition and Summary 
The purpose of this qualitative case study was to explore quality breaks when 
clinical trials are outsourced in Asia Pacific region. In Section 2, I described the (a) 
researcher role, (b) the participants for the study, (c) the research method and design, (d) 
population sampling, (e) ethical research, (f) data collection and organization techniques, 
(g) data analysis, and (h) the reliability and validity of the study. In Section 3, I will 
describe the application to practice and implication for change. I will provide a detail 
description of the following (a) overview of the study, (b) presentation of the findings, (c) 
application to professional practice, (d) the implications for social change, (e) 
recommendations for action, (f) recommendation for further research, (g) reflections, and 
(h) study conclusions. 
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Section 3: Application to Professional Practice and Implications for Change 
Introduction 
The purpose of this qualitative case study was to explore strategies clinical quality 
assurance managers use to avoid a breakdown in quality with outsourced clinical trials in 
Asia-Pacific countries. In this study, I conducted semistructured interviews with 15 
clinical quality assurance senior managers to explore strategies on how to avoid quality 
system breakdowns with outsourced clinical trials. The three emergent themes that I 
identified from the participants’ interviews were the following (a) quality vendor 
management of outsourced vendors, (b) building quality in outsourced clinical trials, and 
(c) quality management system. All of the research participants reported that to improve 
quality and avoid quality breaks with a clinical trial, managers should maintain a robust 
quality management system and closely monitor the outsourced vendor. The research 
participants also reported that a close relationship between vendor and client 
characterized by trust and communication correlated to outsourcing success. The final 
strategy, which the majority of the research participants reported to be the principle 
method for research and development to maintain and improve drugs and service quality, 
was implementation of a quality management system. Exploration of the clinical quality 
assurance outsourcing strategies may provide process improvements to the outsourcing 
clinical trial business model, higher quality submissions to regulatory agencies, and a 




Presentation of the Findings  
The overarching research question for this study was the following: What strategies 
do clinical quality assurance managers use to avoid quality breakdowns with the 
outsourced clinical trials in Asia-Pacific countries ? To answer the overarching research 
question the following open-ended semistructured interview questions asked were: 
1. How do clinical quality assurance managers regulate the clinical quality 
management systems and adapt to changes when trials are outsourced to 
Asia Pacific?  
2. How do clinical quality assurance managers ensure that clinical trial 
vendors adapt to the changes in the environment and process negative 
feedback?  
3. What actions are taken by clinical quality assurance managers to ensure 
outsourced clinical trial vendors are following the agreed contracts?  
4. What strategies do clinical quality assurance managers employ to ensure 
compliance from an outsourced clinical trial vendor after an agreed 
quality contract? 
5. What are some risks and benefits associated with clinical trials when 
outsourced to Asia Pacific? 
6. How do clinical quality assurance managers build successful relationships 
with clinical trial vendors and sustain those relationships with an ever-
changing outsourcing business model?  
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7. How do clinical quality assurance managers ensure standard methods of 
communication of newly released standard operating processes, 
regulations, systems, and tools to outsourced clinical trial vendors?  
8. In a 1-year time frame, how often do clinical quality assurance managers 
and outsourcing vendors reassess quality agreements, contracts, 
processes, and potential gaps? 
9. What strategies have/have not worked with outsourcing clinical trials to 
ensure the highest quality of the clinical trial?  
10. Is there any additional information you would like add that I may not 
have addressed by the interview questions? 
To explore clinical quality assurance managers’ strategies to avoid quality breaks 
with outsourced clinical trials, a qualitative case study was the optimal approach. Due to 
the XYZ pharmaceutical organization’s policy on audio recording, the face-to-face 
interviews were not audio recorded. However, the face-to-face interviews were 
transcribed from notes taken during the interview into Word documents and sent to the 
research participants for transcript review. I used the NVivo 10 software to assist with the 
coding and analysis of data collected from interviews and questionnaires to identify 
potential themes. I identified three emergent themes: (a) quality vendor management, (b) 
building quality in outsourced clinical trials, and (c) successful management and 





Theme 1: Quality Vendor Management 
 The clinical quality assurance senior managers reported that the strategies to avoid 
quality breaks with outsourced clinical trials were to manage quality oversight of the 
outsourced vendor. To improve quality and avoid quality breaks with a clinical trial, 
vendor should maintain a robust quality management system and closely monitor the 
outsourced vendor. Kennedy, Nordrum, Edwards, Caselli, and Berry (2015) noted the 
following ways to improve vendor quality: (a) build quality culture, (b) provide risk 
management tools and detectors, (c) monitor progress through metrics, (d) communicate 
service standards, and (e) provide education and training. Similarly, Medina and 
Richmond (2015) noted that there were increased numbers of industry-wide quality 
breaches and consequential drug shortages, which fueled FDA interest to improve the 
quality of pharmaceutical organizations. One method for quality improvement involved 
quality metrics by FDA inspectional resources, use of the risk-based paradigms, and 
communication of the quality status of various companies to other stakeholders. Medina 
and Richmond found the most valued metrics within the pharmaceutical organization 
were FDA metrics, such as warning letters and observations. Medina and Richmond 
stated that the survey respondents were hesitant to share information on metrics for key 
process indicators that would signal quality problems sooner. Medina and Richmond 
agreed with the FDA Request for Quality Metrics (2015) that the pharmaceutical 
organization is the most important stakeholder for the development and rating of quality 
metrics. Both Medina and Richmond and the FDA Request for Quality Metrics argued 
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that senior level management’s commitment to quality was a key factor in evaluating the 
overall quality culture within the pharmaceutical organization. 
The results of the research study confirmed findings from similar studies (Kennedy et 
al., 2015; Medina & Richmond, 2015; Temkar, 2015) that quality oversight and 
management were critical to avoiding quality breaks with outsourced clinical trials. 
Examples of research participants’ (coded CQA1-CQA15) responses included were the 
following: 
 “Vendors go through a qualification process, are periodically audited, and are 
monitored on an ongoing basis. Have regular scheduled QA meetings with 
vendors to review/discuss the status of issues and projects.” (CQA7) 
 “Clinical quality assurance has country specific quality assurance associates 
as checkpoints in Asia Pacific to monitor and oversee activities in outsourced 
clinical trial vendors.” (CQA15) 
 “Per procedure, all clinical vendors require some level of oversight by the 
pharmaceutical organization. Larger strategic vendors have operational 
oversight and executive level steering committees to provide high-level 
oversight and feedback. At an operational level, Key Performance Indicators 
are used by study teams to monitor vendor performance and act as an 
indicator that corrective actions must be taken. Key Performance Indicators 
have been standardized for all high risk clinical services.” (CQA8).  
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 “A clinical quality assurance representative is assigned to the study based on 
function the outsourced vendor would provide. This ensures a more focused 
and consistent approach to managing quality breaks.” (CQA4)  
 “CQA holds quarterly contract/statement of work reviews with our vendor as 
well as an annual governance meeting” (CQA5). 
 “A checklist based on the activities delegated to the vendor should be created 
and used as a tool for the continuous oversight of the vendor. This can be 
carried out by on site audits, review of resulting data or questionnaires to the 
vendor that request documented evidence of fulfilment of the contract 
requirements.” (CQA6). 
 “Frequent audits, particularly close audits of CVs and training records are 
certainly important to ensure the appropriate personnel are being assigned as 
per the contract—which should specify clear and detailed requirements. In 
addition, a sound signals detection program is needed that incorporates data 
management oversight at the sponsor as well as automated monitoring of the 
data and documentation on an ongoing basis.” (CQA1) 
 “The only way to actually determine if vendors are following conditions in the 
contracts is to audit them and hold them accountable to a Corrective Action 
plan.” (CQA9). 
 “The strategies we use to ensure quality at outsourced clinical trials is using 




 This is a very delicate aspect, and needs to be handled as such. Stability in 
how the vendor relationship is managed is essential, particularly during the 
post-qualification trial execution phase, where robust vendor oversight and 
close collaboration between sponsor and CRO are the key items to look at.” 
(CQA11) 
 The qualification of clinical vendors and outsourcing of clinical trial activities 
is performed via an approved XYZ pharmaceuticals standard process, 
irrespective of the region where the services will be performed. This process 
has been designed to take into account the risks associated with the service 
being outsourced (primarily looking at risks to patient safety and data integrity 
so that providers of similar services are assessed via process and level of 
scrutiny).” (CQA8) 
Research participants reported that vendor quality management of the outsourced 
clinical vendor was essential to avoid any quality breaks. To establish quality oversight to 
outsourced vendors, clear metrics should be determined and communicated to vendors to 
ensure continuous quality. Clinical quality assurance senior managers should work with 
specific clinical quality assurance groups and vendor operational excellence teams to 
assess vendor and quality vendor contract agreements. The majority of the research 
participants agreed that auditing vendors and implementing corrective and preventative 
action plans enhances vendor accountability. Furthermore, the majority of the research 
participants noted that the creation of a quality governance board was a key success 
factor in vendor quality management. The quality governance board assisted both the 
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clinical quality assurance managers and outsourced vendors to discuss quality issues, 
audits, corrective and preventative actions, and current challenges. The board also 
provided a platform to escalate potential risk and quality issues. 
The FDA Warning Letters (2015) noted that the even though the clinical trials are 
outsourced to vendors, the ultimate responsibility and accountability for the clinical trials 
is with the pharmaceutical organization. The expectation of the FDA is pharmaceutical 
organizations perform vendor quality management (FDA Warning Letters, 2015). Recent 
FDA warning letters issued to the pharmaceutical organizations were due to lack of 
vendor oversight of the contract research organizations (FDA Warning Letters, 2015). 
Research participants supported implementing the vendor quality management program 
to avoid quality breaks with outsourced clinical trials not only in Asia Pacific but in all 
geographical regions of outsourced clinical trials. 
Theme 2 Building Quality in Outsourcing Clinical Trials 
Awareness of risks and benefits. The increased growth in outsourcing, 
specifically with clinical trials, was triggered by pharmaceutical organizations’ effort to 
reduce cost and focus on strategic plans (Abdul-Halim, Ee, Ramayah, & Ahmad, 2014). 
The driving factor for many pharmaceutical organizations to outsource clinical trials and 
clinical line functions was to reduce drug development cost and patient recruitment. The 
outsourcing of various clinical line functions within R&D to CRO or BPO has been an 
increasing trend (Huysmans et al., 2014) among pharmaceutical organizations to achieve 
faster regulatory approval timelines. However, the majorities of the outsourcing projects 
have been prone to failure (Huysmans et al., 2014) and have ultimately increased costs 
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for pharmaceutical organizations to repair the damage. When any functionality of clinical 
trial is outsourced, there are risks and benefits. The ultimate key question is do the 
benefits outweigh the risks? If so, how can pharmaceutical organizations ensure high 
quality and success with the outsourcing? The majority of the research participants 
reported that there is far more risk than benefits when outsourcing to Asia Pacific. The 
following are examples of the research participants’ responses: 
• “In the past, we have seen that some risks include lack of clinical trial 
support experience at the vendor and extremely high vendor personnel 
turnover. This can be disruptive to the management of the trial.” (CQA8) 
• “One risk to outsourcing to Asia Pacific is high turnover rate with Data 
Management and Information Technology associates which leaves no 
consistency and information lost and having to retrain new associated to 
projects” (CQA14)  
• “Language barriers, time zone differences, lack of understanding clinical 
protocols and clinical processes.” (CQA2) 
• “Risks are: cost savings are not as great as expected, underestimation of 
the effort needed for ongoing quality/compliance, vendors lack experience 
and high turnover of associates at vendors, weak with soft skills.” (CQA7) 
• “Risks may include a general language barrier, where the written and 
spoken language in Asia Pacific are dramatically different that the EU and 
US. In addition, local customs and regulations are solely managed by the 
CPO. If the CPO is not well staffed, trained, or otherwise equipped, they 
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may work in a vacuum and can miss important coordination with Global 
partners.” (CQA10)  
• “Such relationships are particularly vulnerable to distance, time 
differences and assurance of adequate training in regulations and guidance. 
Potential delays in communication or vendor may need immediate 
assistance with an emergent situation during hours when US counterparts 
are typically unavailable.”(CQA5) 
Research respondents had similar perceptive on risks, as well as, benefits. The two 
major benefits that majority of the research participants discussed was cost benefits and 
participant pool population for targeted diseases in the Asia Pacific region. Examples 
such as: 
• “Cost savings are meant to be the primary benefit.” (CQA1) 
• “Benefits clearly include adequate penetration and enhanced 
understanding of local markets and related challenges, as well as favorable 
costing.” (CQA11)  
• “In my experience, one of the benefits of clinical trials outsourced to Asia 
is cost, i.e. lower cost than the rest of the world. There is a large pool of 
skilled resource. (CQA4)  
Research participants’ responses on the benefits and risks associated with outsourced 
clinical trials confirmed with current, as well as, past literature reviews (Abdul-Halim et 
al., 2014; Huysmans et al., 2014; Mariani et al., 2014) on the risks and benefits for 
outsourcing clinical trials. Research participants concurred having a quality risk 
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management system and tools in place for data signal detection helped to determine what 
clinical trials and clinical trial site were at higher risk.  
Stronger vendor-client relationship. The majority of the research participants 
reported that building better vendor-client relationships may enhance quality services by 
minimizing quality risks with clinical trials. St. John, Guynes, and Vedder (2014) 
conducted a study on the complexity of the IT vendor-client relationship, examined social 
exchange factors difficult to address in vendor contract agreements, and the success 
factor for vendor-client relationships. Their participants stated that a close relationship 
between vendor and client characterized by trust and communication correlated to 
outsourcing success (St. John et al., 2014). Similarly, a case study conducted by Moe, 
Šmite, Hanssen, and Barney (2014) reported that companies had challenges with poor 
communication, high turnover employee rate, domain knowledge, a lack of commitment 
of external developers, as well as, cultural challenges. The termination of all four medium 
sized outsourcing companies resulted because of low quality services. Research 
participants’ responses were consistent with literature reviews (Moe et al., 2014; 
Schwarz, 2014; St. John et al., 2014 & Qui & Chan, 2015), which reflected in their 
response to build better vendor-client relationships: 
• “Good communication, clear escalation paths, and continuous involvement 
QA can use their broad experience to provide advice about the planned 
clinical trial procedures. They can give an independent viewpoint, 
uninfluenced by other project concerns or pressures.” (CQA6) 
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• “Regular, transparent communication and modeling integrity in vendor 
relationships encourages the flexibility and rapid response necessary to 
meet/exceed quality standards and adjust when needed.” (CQA5) 
• “The clinical quality assurance also tracks trends on quality breaks and 
discusses with the vendors where the same type of quality break occurs 
more frequently than normal.” (CQA4) 
Similarly, St. John, Guynes, and Vedder (2014) noted lack of communication 
between client and vendor leads to lack trust, which leads to relationship failure. Time is 
a key element on why the vendor-client relationship fails. The failure of the relationship 
contributed to individuals who are too busy, separated by distance, time zones, and 
language barriers. A common recommendation to build successful vendor-client 
relationship is to communicate at least 10 minutes per day (St. John et al., 2014). Some 
research participants felt vendor-client relationship could use improvement so clinical 
quality assurance could be more proactive instead of reactive: 
• “Setting up of regular meetings with the vendor and being pro-active. 
Unfortunately, I don’t believe we do this very well and with all that we 
have in place, we are still in a reactive mode.”(CQA9). 
• “Unfortunately there is still lack of communication between various 
outsourcing vendors, IT, and the clinical line functions. It seems when 
quality breaks occurs that is when all parties come together to discuss in 
the reactive mode.” (CQA13) 
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The majority of the research participants’ responses aligned with Qi and Chau (2015) 
stating the keys to building a successful vendor-client relationship are communication 
and trust. Both literature reviews and research participants’ responses concluded that 
having, maintaining, and building vendor-client relationships contribute to better quality 
services and decrease quality breaks. 
Theme 3: Successful Management and Implementation of QMS 
The majority of the research participants’ felt that the principle method for research 
and development to maintain and improve drugs and service quality is through successful 
management and implementation of a quality management system. All of the research 
participants’ felt implementing and maintaining the quality management system provided 
document controls, controlled systems, standard operating processes, regulatory 
requirements, and training provided better quality services. The following are ways that 
clinical quality assurance managers regulate quality management systems, so it protects 
and adapt to changes when clinical trials are outsourced to Asia Pacific: 
• “Ensure SOPs and other documents are in place and involved personnel 
are appropriately trained. Ensure compliance is being monitored.” 
(CQA12) 
• “Ensure that internal guidance is aligned with local/regional health 
authorities and to ensure the outsourcing partners are trained and evaluated 
for compliance on a regular basis.” (CQA5) 
• “Clinical QA needs to actively monitor activities performed by the 
business, as well as performing their own reviews of SOPs at the vendor 
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and requiring corrective action for deficiencies found. SOPs in Asia 
Pacific need to be highly detailed, much more so that QA is accustomed to 
seeing and requiring.” (CQA1) 
• “We have quality risk management tools and systems that give provide us 
signal detection on the possible risks that exist at clinical sites to help 
determine what sites may need to be audited.” (CQA15) 
In addition, research participants agreed that the way to ensure the quality 
management system adapt to changes in its environment, process negative feedback, and 
produce stable equilibrium is by setting up quality management standards, such as ISO 
9000. Many of the research participants agreed that the key critical success factors of 
implementation of QMS are communication from R&D senior management and R&D 
colleagues who understand the importance of it. However, one research participant 
responded that negative feedback process could be challenging and focus should be more 
process oriented than personnel.  
• “Negative feedback is particularly challenging culturally. I think keeping 
the focus as much as possible on procedures rather than on personnel can 
be helpful, but it is very important to work on developing an attitude of 
quality vigilance and self-reporting on the part of the local personnel and 
management.”(CQA1) 
I noted the results of the study tied into existing literature, which showed that for an 
organization to increase performance and quality services a QMS must be successfully 
implemented. (Li, TU, & Lui, 2015; Kaziliūnas, 2010; Zelnik, Maletič, & Gomišček, 
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2012).  Kaziliūnas (2010) also noted that a quality management system based on 
international standards, such as ISO 9000, may enhance quality performance and 
services. Similarly, Zelnik et al. (2012) discussed that the organization’s senior leaders 
need to motivate and understand the ISO 9000 standards, as well as, commitment to 
successfully implement a QMS. One reason QMS is not implemented successfully is the 
lack of involvement from both senior management and all employees (Zelnik, et al., 
2012). Both literature (Calabrese & Corbò, 2014; Kaziliūnas, 2010; Li et al., 2014) and 
research participants’ responses aligned on how to successfully implement and manage a 
QMS to produce higher quality product and services.  
The results of the research study aligned  with the study’s conceptual framework of 
the general systems theory. According to the general systems theory, environmental 
influences and time causes the whole system, as well as, its subsystem to be out of 
balance and less maintained and controlled (Calabrese & Corbo, 2014; Kaziliūnas, 2010; 
Stacey, 2011). Pharmaceutical managers used system thinking as a way to resolve 
complex problems and designs. Leaders utilizing system thinking seemed to be at an 
advantage for managing complex situations and uncertainty where there is no simple 
situation. I noted the results of the research study confirmed with the existing literature 
on effective business practice. Schmiedel, vom Brocke, and Recker (2015) noted that 
organization’s culture plays a key role in the success or failure of a business practice to 
be effective. In many organizations to measure if a business process is effective or not, 
heavily relies on the organizational culture of self-reporting to report gaps or deviations 
within the process. Research participants’ responses concurred with the literature that for 
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a process to be effective there needs to be self-awareness and self-reporting culture to 
address quality issues or gaps in the process. Many researcher participants’ felt the need 
for clear communications of the new processes, training, audit findings and 
standardizations across various business line functions would improve compliance. 
Applications to Professional Practice 
The purpose of this qualitative case study was to explore what strategies some 
clinical quality assurance managers use to avoid breakdowns in quality with outsourced 
clinical trials in Asia-Pacific countries. I identified three emergent themes to avoid 
quality system breaks in outsourced clinical trials. The results of the study revealed that 
strong vendor-client relationships, vendor quality management, and a successfully 
implemented and managed QMS were key success factors to maintain and sustain high-
quality in outsourced clinical trials business practices. The majority of the research 
participants’ felt that building strong vendor-client relationships with key business line 
functions, outsourcing clinical vendors and quality assurance managers were essential to 
building trust. The research participants’ felt that attending quality review board meetings 
and governance steering committees to discuss ongoing challenges, metrics, risks, 
processes, and having an open and clear communication on a regular basis assisted in 
building effective quality processes. Qi and Chau (2015) study results aligned with 
research participants’ responses that the leading success factors on the outsourcing 
relationship in China were the successful formation of vendor-client relationship through 
communication, quality, and trust. Wong, Tseng, and Tan (2014) noted to boost 
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organizations’ performance they need to configure business processes and a quality 
culture model for the team performance to improve continuously.  
The research participants stated senior management and employees need to 
commit to the QMS to produce high-quality product and services. Zelnik et al. (2012) 
also agreed that organization’s senior management should have motivation and 
understanding of the ISO 9000 standards, as well as, a commitment to quality to 
implement a QMS. Pharmaceutical organizations utilized quality management systems to 
improve the quality of product and process to achieve continuous customer satisfaction 
(Khanna, Sharma, & Laroiya, 2011).  
Implementation of quality remains an important issue for global organizations, 
which are continuously trying to improve their competitiveness (Khanna et al., 2011; 
Johnson & Gupta, 2013). To gain global competitive advantage and to avoid quality 
system breaks in outsourcing clinical trials, pharmaceutical business leaders can 
incorporate these strategies to build quality within their organization. Also, the research 
data provides insight to the leaders how to improve vendor-client relationships to build a 
better relationship with internal resources and outsourcing vendor resources (Mendivil, 
2012).  
Implications for Social Change 
The results of this study might bring about social change by improving strategies 
for various organizations’ senior leaders to improve business relationships and producing 
high-quality products to the customer. Senior leaders may want to use this information 
for positive social change by creating quality culture awareness and commitment at all 
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levels of management from both the vendor and organization. The quality culture 
commitment from senior leaders may enhance the self-reporting culture; provide 
empowerment and accountability amongst employees. 
The data from this study may also assist communities economically by creating 
quality assurance job opportunities globally to monitor the quality of products and 
services. The quality improvements with outsourced clinical trials may produce a better, 
more effective, safer drug to society. The quality improvements made within the clinical 
trial processes may provide better knowledge of the quality of the drug, as well as, drug 
side effects, which will enhance drug’s side effects reporting to federal agencies. 
Furthermore, the data from the study may improve individuals’ knowledge of the quality 
of the drug and change their behavior by self-reporting their drug side-effects back to the 
organization to improve drug labeling. Ultimately, enhancing drug label information may 
assist physicians to dose patients accordingly and to inform better the patients of known 
side-effects.  
Recommendations for Action 
Pharmaceutical business leaders need to secure funding for quality commitments 
and programs for clinical quality assurance managers to ensure proper quality oversight 
to the outsourced clinical vendor. Such funding should cover frequent travel to build 
vendor relationships, conduct audits, and provide training to enhance quality with 
vendors. The clinical quality assurance managers, as well as R&D senior leaders, need to 
communicate their quality commitments throughout the organization and implement a 
sustainable quality plan. 
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Kennedy et al. (2015) noted the ways to improve vendor quality were the 
following: (a) build quality culture, (b) provide risk management tools and detectors, (c) 
monitor progress through metrics, (d) communicate service standards, and (e) provide 
education and training. Senior leaders should be aware and plan for offshoring BPO’s 
cultural risk factors that often occur with client and vendor relationships (Holbrook, 
2011; Mosher & Mainquist, 2011) to avoid future quality problems. Culture plays a 
significant role when dealing with offshoring vendors. Communications, management 
style, understanding each other culture, gender issues, quality management, and team 
harmony are at risk if client and vendor have a serious communication break (Holbrook, 
2011). Both Medina and Richmond and the FDA Requst for Quality Metrics (2015) 
argued that senior level management’s commitment to quality was a key factor in 
evaluating the overall quality culture within the pharmaceutical organization. 
The study results would be the most beneficial for the R&D senior leaders. The 
strategies identified from this study could provide R&D senior leaders with approaches to 
avoid a breakdown in quality with outsourced clinical trials. Prior to this research, there 
was limited information on how to avoid quality system breaks in outsourced clinical 
trials. For the study results to reach a wider audience, the results should be disseminated 
through business journals and scholarly literature. The results of this study may assist 
pharmaceutical organization leaders gain insights on how to improve their outsourcing 




Recommendations for Further Research 
My recommendations for future research and improvements in business practices 
are to duplicate this study from different global regions and different sample populations. 
The clinical quality assurance managers have a robust quality background and training to 
analyze risk and detect quality issues within clinical trials. The reason, I would 
recommend another sample population, such as clinical trial managers is to gain insight 
on the ongoing quality breaks seen in outsourced clinical trials. A different sample 
population will bring further insights to pharmaceutical senior leaders to enhance quality 
strategies and practices. My final recommendation is to study the practices of clinical 
outsourced vendors from various geographic regions. The information from such studies 
may provide insight and strategies to enhance quality business practices.  
 In research studies, there are limitations or weaknesses, and this study is no 
exception. Two limitations of this research study were that I only explored one 
multinational pharmaceutical organization and did not explore medium nor small size 
pharmaceutical organizations. I recommend other researchers to explore numerous and 
various sized pharmaceutical organizations to gain further strategies to avoid quality 
system breaks. Duplication of this study from different global regions and from a small to 
medium size pharmaceutical organizations may determine if clinical quality assurance 
managers’ strategies are different or similar to this study. Another limitation to this study 
was only including pharmaceutical organization and not CROs, BPOs, and biotech 
organizations. My final research recommendation is to explore strategies that senior 
leaders of outsourcing vendors utilize to avoid quality breaks. Exploring the strategies of 
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outsourcing vendor management’s leaders may assist R&D pharmaceutical leaders to 
enhance quality business practices and outsourcing models.  
 
Reflections 
This study was a success in exploring what strategies some clinical quality 
assurance managers use to avoid a breakdown in quality with outsourced clinical trials in 
Asia-Pacific countries. As a clinical quality assurance manager within the organization 
from one sector of the overall development quality assurance organization, it was not 
clear to me why quality breaks occur to outsourced Asia-Pacific clinical trials. I needed 
additional clarity on why some pharmaceutical organizations seem more successful than 
others. Over the last 10 years, an increasing trend for pharmaceutical organizations to 
outsource clinical trials and clinical line functions to Asia Pacific. Asia-Pacific countries 
are the most sought out destination for clinical trials, which raised interest in the quality 
of outsourced clinical trials. My curiosity grew over the years; however, there was very 
little research on quality aspect clinical trials and ways to improve outsourced clinical 
trials to avoid quality breaks. The information of this study showed me that even though 
various clinical quality assurance managers, from various concentrations of the clinical 
trials, participated in the study, they all agreed on the strategies to avoid quality breaks in 
outsourced clinical trials. While a few research participants were business colleagues and 
my career is within the clinical quality assurance arena, I utilized reflexivity to check for 
sources of personal bias. I used the methodological triangulation to ensure validity within 
the research study. The data collected from interview transcripts and documentation such 
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as field notes, government reports, literature reviews, and the XYZ pharmaceutical 
organization’s quality report provided validity. I ensured study reliability by member 
checking to verify the accuracy of my interpretations.  
Summary and Study Conclusions 
The high cost of conducting clinical trials forces the pharmaceutical leaders to 
outsource clinical trials to developing countries. The outsourced clinical trial model saves 
money, time, provides faster drug approval, and provides patient recruitment when 
clinical trials are outsourced (Mendivil, 2012). Consequently, globalization of the clinical 
trials increases complexity, as well as, making it difficult to achieve global quality and 
patient safety (Paul et al., 2011). In developing countries, 1,589 out of 1,940 drugs are 
identified as registered, and there were 351 drugs not registered with limited information 
on drug's clinical trials and known side effects (Bate, Mooney, & Hess, 2011). Because 
of the complexity of the clinical trials and faster completion timelines, drugs’ side effects 
are underreported and causing thousands of deaths, hospitalization due to tragedies, and 
lack of drug registry (Soni & Singh, 2013) 
 The pharmaceutical senior leaders should address outsourced clinical trial risks 
and complexities by creating sustainable quality management plans to avoid quality 
system breakdowns in outsourced clinical trials. The results of this study indicated that 
building vendor-client relationships, having vendor quality management and successful 
implementation of QMS can help avoid quality system breaks. The ultimate goal for both 
pharmaceutical organizations and outsourced clinical vendors is bringing the safest and 
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Appendix A: Consent Letter for Participant over 18 Years of Age  
You are invited to take part in a research study titled Total Quality Systems breakdowns of 
Outsourcing Clinical Trials. The research objective is to improve quality of outsourced 
clinical trials in Asia Pacific developing countries. The researcher is inviting Quality 
Assurance Managers who have experience in the clinical arena in the pharmaceutical industry and 
have worked with outsourced vendors to be in the study. This form is part of a process called 
“informed consent” to allow you to understand this study before deciding whether to take part. 
 
This study is being conducted by a researcher named Hemali Barrios, who is a doctoral student at 
Walden University. You may already know the researcher as a Quality Assurance colleague, but 
this study is separate from that role. 
 
Background Information: 
The purpose of this study is to explore what strategies some clinical quality assurance 
managers use to avoid a breakdown in quality with outsourced clinical trials in Asia-
Pacific countries. The information provided by clinical quality assurance managers may 
contribute to social change through the creation of strategies to avoid quality breakdowns 
with outsourced clinical trials. 
 
Procedures: 
If you agree to be in this study, you will be asked to:  
 Attend thirty to forty five minute interview session either face-to-face or telephone 
interview. After each interview you will be asked to review interview transcripts for 
accuracy. 
  If either interview session is not viable then e-mail questionnaire will be sent to you to 
return to the researcher within three business days from receipt. 
 A follow up 15-30 minute session may be needed if the researcher needs to clarify your 
interview answers or if you would like additional sessions to further add to the interview 
questions 
 
Here are some sample questions: 
1. How do clinical quality assurance manage to regulate the clinical quality 
management systems, so it protects and adapt to changes when outsourced to 
Asia Pacific?  
2. What are some risks and benefits associated with clinical trials when outsourced 
to Asia Pacific? 
 
 
Voluntary Nature of the Study: 
This study is voluntary. Everyone will respect your decision of whether or not you choose to be in 
the study. No one at Novartis Pharmaceuticals Cooperation will treat you differently if you decide 
not to be in the study. If you decide to join the study now, you can still change your mind later. 





Risks and Benefits of Being in the Study: 
Being in this type of study involves some risk of the minor discomforts that can be encountered in 
daily life, such as, stress or being uncomfortable being interviewed. Being in this study would not 
pose risk to your safety or wellbeing. The benefit of being in the study is providing information 
that can help improving quality for outsourced clinical trials. 
 
Payment: 




Any information you provide will be kept confidential. The researcher will not use your personal 
information for any purposes outside of this research project. Also, the researcher will not include 
your name or anything else that could identify you in the study reports. Data will be kept secure 
by encrypted, and password protected computer files and labeled by the participant's coded name 
on the researcher personal computer. Data will be kept for a period of at least 5 years, as required 
by the university. 
 
Contacts and Questions: 
You may ask any questions you have now. Or if you have questions later, you may contact the 
researcher via 862-345-0642. If you want to talk privately about your rights as a participant, you 
can call Dr. Leilani Endicott. She is the Walden University representative who can discuss this 
with you. Her phone number is 612-312-1210. Walden University’s approval number for this 
study is IRB approval is 09-01-15-0155581 and it expires on August 31 2016. 
 
The researcher will give you a copy of this form to keep, if you choose a face-to-face interview. 
 
Please print or save this consent form for your records if you choose to do an e-mail questionnaire 
or telephone interview 
 
Statement of Consent: 
 
I have read the above information and I feel I understand the study well enough to make a 
decision about my involvement. By signing below, or replying to this e-mail with the words, “I 
consent”, I understand that I am agreeing to the terms described above. 
 
 
Printed Name of Participant  
Date of consent  
Participant’s Signature  
Researcher’s Signature  
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Appendix B: Interview Questions 
1. How do clinical quality assurance managers regulate the clinical quality 
management systems and adapt to changes when trials are outsourced to Asia 
Pacific?  
2. How do clinical quality assurance managers ensure that clinical trial vendors 
adapt to the changes in the environment and process negative feedback?  
3. What actions are taken by clinical quality assurance managers to ensure 
outsourced clinical trial vendors are following the agreed contracts?  
4. What strategies do clinical quality assurance managers employ to ensure 
compliance from an outsourced clinical trial vendor after an agreed quality 
contract? 
5. What are some risks and benefits associated with clinical trials when outsourced 
to Asia Pacific? 
6. How do clinical quality assurance managers build successful relationships with 
clinical trial vendors and sustain those relationships with an ever-changing 
outsourcing business model?  
116 
 
7. How do clinical quality assurance managers ensure standard methods of 
communication of newly released standard operating processes, regulations, 
systems, and tools to outsourced clinical trial vendors?  
8. In a 1-year time frame, how often do clinical quality assurance managers and 
outsourcing vendors reassess quality agreements, contracts, processes, and 
potential gaps? 
9. What strategies have/have not worked with outsourcing clinical trials to ensure 
the highest quality of the clinical trial?  
10. Is there any additional information you would like add that I may not have 
addressed by the interview questions? 
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This is to notify you that Walden University Doctoral student Hemali Barrios is 
conducting a research study titled Total Quality Systems breakdowns of Outsourced 
Clinical Trials. The purpose of this qualitative case study is to explore pharmaceutical 
leaders’ procedural policies to ensure that outsourcing companies use proper quality 
clinical trial processes. This knowledge ensures outsourcing companies use proper 
quality clinical trial processes in order to enhance data quality of the clinical trial. 
 
Your participation will consist of a 30 minute interview session. This study is voluntary. 
Everyone will respect your decision of whether or not you choose to be in the study. No 
one at Novartis Pharmaceutical organization will treat you differently if you decide not to 
be in the study. If you decide to join the study now, you can still change your mind later. 
You may withdraw any time during the research study. Any information provided during 
the study is confidential. Feel free to contact me to express your interest in participation. 
 














Appendix D: Confidentiality Agreement 
 
Name of Signer: Hemali Barrios    
     
During the course of my activity in collecting data for this research: “Total Quality 
System Breakdown in Outsource Clinical Trials” I will have access to information, which 
is confidential and should not be disclosed. I acknowledge that the information must 
remain confidential, and that improper disclosure of confidential information can be 
damaging to the participant.  
 
By signing this Confidentiality Agreement I acknowledge and agree that: 
1. I will not disclose or discuss any confidential information with others, including 
friends or family. 
2. I will not in any way divulge, copy, release, sell, loan, alter or destroy any 
confidential information except as properly authorized. 
3. I will not discuss confidential information where others can overhear the 
conversation. I understand that it is not acceptable to discuss confidential information 
even if the participant’s name is not used. 
4. I will not make any unauthorized transmissions, inquiries, modification or purging of 
confidential information. 
5. I agree that my obligations under this agreement will continue after termination of 
the job that I will perform. 
6. I understand that violation of this agreement will have legal implications. 
7. I will only access or use systems or devices I’m officially authorized to access and I 
will not demonstrate the operation or function of systems or devices to unauthorized 
individuals. 
 
Signing this document, I acknowledge that I have read the agreement and I agree to 
comply with all the terms and conditions stated above. 
 




Appendix E: Protecting Human Research Participants 
 
   
 
Certificate of Completion 
The National Institutes of Health (NIH) Office of Extramural Research 
certifies that Hemali Barrios successfully completed the NIH Web-
based training course “Protecting Human Research Participants”. 
Date of completion: 07/09/2013  
Certification Number: 1210496  
 
 


















One Health Plaza 
East Hanover, NJ 07936 
 
Tel  862-778-8454 












July 23, 2015 
 
 
Dear Hemali Barrios,  
  
Based on my review of your research proposal, I give permission for you to conduct the 
study entitled Total Quality Systems breakdowns in Outsourced Clinical Trials within the 
Novartis Pharmaceutical Corporation. As part of this study, I authorize you to gain access 
to the purposive sample of clinical quality assurance managers from an invitation via e-
mail or through teleconference meeting invitations. In addition, authorization for any 
follow-up question with a phone call or e-mail to answer any questions or concerns the 
participants may have about the study via e-mail, in person, or via teleconference. A copy 
of the approved IRB informed consent will be sent to me prior to obtaining access to 
potential research participants. After participants gave confirmation to volunteer for the 
study, I will authorize you to send an IRB approved informed consent to the clinical 
quality assurance managers via e-mail or in person. According to Novartis policy there 
will be no audio recorded sessions with research participants. I authorize you to collect 
data by conducting semistructured interviews via e-mail, in person, or teleconference. I 
understand the semistructured interview will consist of 10 construct study specific sets of 
open-ended questions and after each interview the researcher will transcribe verbatim the 
interview and will perform a member check with each research participant to review 
transcribed interview scripts to ensure accuracy of the researcher data interpretation. I 
understand that the research study will be published and any Novartis identifiers will be 
de identified. Dissemination of the results will be given to each participants or 
stakeholder by debriefing sessions for overall study results. Individuals’ participation will 
be voluntary and at their own discretion.  
 
We understand that our organization’s responsibilities include: giving access to research 
participants (clinical quality assurance managers), and the use of Novartis conference 
rooms to conduct interviews, and allow review of Novartis policies and quality reports. It 
is assumed that the supervision of the research activities is by Walden’s University’s 
remote faculty members. We reserve the right to withdraw from the study at any time if 




I confirm that I am authorized to approve research in this setting and that this plan 
complies with the organization’s policies. 
 
I understand that the data collected will remain entirely confidential and may not be 
provided to anyone outside of the student’s supervising faculty/staff without permission 


















Global Head, Clinical Quality Assurance 
 
 
 
